Difference between revisions of "T-cell acute lymphoblastic leukemia, pediatric"
Warner-admin (talk | contribs) m (Text replacement - "|Phase IV" to "|Phase 4") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in supplement'''" to "'''dosing details in supplement have been reviewed by our editors'''") |
||
(114 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | {{#lst: | + | <span id="BackToTop"></span> |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
+ | [[#top|Back to Top]] | ||
+ | </div> | ||
+ | {{#lst:Editorial board transclusions|peds}} | ||
+ | ''This page contains studies that were specific to pediatric populations. For the more general T-cell acute lymphoblastic leukemia page, follow [[T-cell acute lymphoblastic leukemia|this link]]. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 6: | Line 10: | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
|} | |} | ||
− | {{TOC limit|limit= | + | {{TOC limit|limit=4}} |
=Guidelines= | =Guidelines= | ||
− | == | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *'' | + | ==NCCN== |
− | + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1496 NCCN Guidelines - Pediatric Acute Lymphoblastic Leukemia]''. | |
− | == | + | =Upfront therapy= |
− | + | ==COG AALL0434 protocol== | |
− | + | <div class="toccolours" style="background-color:#c8a2c8"> | |
− | =COG AALL0434 | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | + | !style="width: 17%"|Study | |
− | == | + | !style="width: 15%"|Dates of enrollment |
− | + | !style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | |
− | + | !style="width: 17%"|Comparator | |
− | {| class="wikitable sortable" style="width: | + | !style="width: 17%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | !style="width: | + | !style="width: 17%"|[[Levels_of_Evidence#Toxicity|Comparative Toxicity]] |
− | !style="width: | ||
− | !style="width: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ Winter et al. 2015 (COG AALL0434)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ Winter et al. 2015 (COG AALL0434)] | ||
|2007-2014 | |2007-2014 | ||
− | |style="background-color:# | + | |style="background-color:#1a9851"|Phase 3 (E-RT-esc) |
+ | |[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior DFS<sup>1</sup> (primary endpoint) | ||
+ | |style="background-color:#ffffbf"|Similar toxicity | ||
|- | |- | ||
|} | |} | ||
− | =====Chemotherapy | + | ''<sup>1</sup>Reported efficacy is based on the 2020 update.'' |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Induction, Arms B (Nelarabine Arms) {{#subobject:1511c2|Variant=1}}=== | ||
+ | '''All Patients''' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
*[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV once on day 4 (OR 5 OR 6) | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV once on day 4 (OR 5 OR 6) | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 | ||
− | |||
*[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV over 1 to 15 minutes once per day on days 1, 8, 15, 22 | *[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV over 1 to 15 minutes once per day on days 1, 8, 15, 22 | ||
− | + | ====Glucocorticoid therapy==== | |
− | + | *[[Prednisone (Sterapred)]] 30 mg/m<sup>2</sup> PO twice per day on days 1 to 28 (Total of 60 mg/m<sup>2</sup>/day, DO NOT TAPER) | |
− | + | ====CNS therapy, prophylaxis==== | |
− | *[[Cytarabine (Ara-C)]] IT once | + | *[[Cytarabine (Ara-C)]] IT once at time of diagnostic lumbar puncture or Day 1 |
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Initial Dose | ! style="width: 25%" |Initial Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|30 mg | |30 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|50 mg | |50 mg | ||
|- | |- | ||
− | | | + | |3.00 or older |
|70 mg | |70 mg | ||
|} | |} | ||
− | + | *[[Methotrexate (MTX)]] IT once per day on days 8, 29 (CNS3 patients on days 15, 22 ALSO) | |
− | *[[Methotrexate (MTX)]] IT once per day on days 8 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''29-day course''' | |
− | '''29 | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | == | + | ===Consolidation, Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine {{#subobject:ae17db|Regimen=1}}=== |
− | |||
− | # | ||
− | |||
− | |||
− | ===Consolidation | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ||
− | =====Preceding treatment | + | <div class="toccolours" style="background-color:#cbd5e8"> |
− | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Prednisone|Daunorubicin, Pegaspargase, Vincristine, Prednisone | + | ====Preceding treatment==== |
− | =====Chemotherapy | + | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Prednisone|Daunorubicin, Pegaspargase, Vincristine, Prednisone]] induction |
− | *[[Cyclophosphamide (Cytoxan)]] | + | </div> |
− | **Must reduce urine specific gravity to | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> IV over 1 | + | ====Chemotherapy==== |
+ | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day over 30 minutes on days 8, 50 | ||
+ | **Must reduce urine specific gravity to less than or equal to 1.015 prior to administration | ||
+ | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> IV over 1 to 30 minutes or SC once per day on days 8 to 11, 15 to 18, 50 to 53, 57 to 60 | ||
*[[Mercaptopurine (6-MP)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21, 50 to 63 | *[[Mercaptopurine (6-MP)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21, 50 to 63 | ||
**DO NOT escalate or modify dose based on blood counts during this course. | **DO NOT escalate or modify dose based on blood counts during this course. | ||
*[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV once per day over 60 minutes on days 1 to 5, 43 to 47 | *[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV once per day over 60 minutes on days 1 to 5, 43 to 47 | ||
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IM or IV over 1 | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IM or IV over 1 to 2 hours once per day on days 22 & 64 |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> ( | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 22, 29, 64, 71 |
− | ====CNS prophylaxis==== | + | ====CNS therapy, prophylaxis==== |
*[[Methotrexate (MTX)]] IT on days 15, 22, 57, 64 (Omit Day 22 if CNS3 T-ALL) | *[[Methotrexate (MTX)]] IT on days 15, 22, 57, 64 (Omit Day 22 if CNS3 T-ALL) | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | *[[External_beam_radiotherapy|Whole-brain irradiation]] by the following risk-based criteria: | |
− | *[[External_beam_radiotherapy|Whole-brain irradiation]] | ||
**CNS3 T-ALL: 1,800cGy in 10 once daily fractions. | **CNS3 T-ALL: 1,800cGy in 10 once daily fractions. | ||
**Intermediate/High Risk ARM B: 1,200 cGy in 8 once-daily fractions given during weeks 4 and 5 of consolidation | **Intermediate/High Risk ARM B: 1,200 cGy in 8 once-daily fractions given during weeks 4 and 5 of consolidation | ||
− | |||
'''71-day course''' | '''71-day course''' | ||
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *Interim maintenance | + | *Interim maintenance |
− | + | </div></div><br> | |
− | == | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Interim Maintenance, with Capizzi MTX (Arms A and B) {{#subobject:9d711b|Variant=1}}=== | |
− | # | ||
− | |||
− | |||
− | ===Interim Maintenance with Capizzi MTX | ||
− | Arms A and B | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ||
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
====Preceding treatment==== | ====Preceding treatment==== | ||
*[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] induction | *[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] induction | ||
− | + | </div> | |
− | =====Chemotherapy==== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | + | ====Chemotherapy==== | |
*[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 | ||
**If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose. | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose. | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41 | ||
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IM or IV over 1 | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IM or IV over 1 to 2 hours once per day on days 2, 22 |
− | + | ====CNS therapy, prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on days 1, 31 | |
− | |||
− | *[[Methotrexate (MTX)]] IT once on days 1 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | '''56 | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | == | + | ===Delayed Intensification, Nelarabine Arms (Arms B and D) {{#subobject:9d711b|Variant=1}}=== |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | # | ||
− | |||
− | |||
− | ===Delayed Intensification ( | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (max dose 2 mg) on days 1, 8, 15, 43, 50 |
− | + | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once on day 29 | |
− | *[[Cyclophosphamide (Cytoxan)]] | + | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39 |
− | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> | + | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV push/infusion over 1 to 15 minutes once per day on days 1, 8, 15 |
− | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV push/infusion over 1 | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IM or IV over 1 to 2 hours on day 4 (OR 5 OR 6), 43 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IM or IV over 1 | + | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> PO once per day on days 29 to 42 |
− | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> | + | **Should not be given to patients receiving CRT (Arm D and CNS3 T-ALL patients) |
− | **Should not be given to patients receiving CRT (Arm D and CNS3 T-ALL patients) | + | *[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV 60 minutes once per day on days 29 to 33 |
− | *[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV 60 minutes once per day on days 29 | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 7, 15 to 21 (10 mg/m<sup>2</sup>/day, divided twice per day). | |
− | + | ====CNS therapy, prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on days 1, 29, 36 | |
− | *[[Methotrexate (MTX)]] IT once on days 1, 29, | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | ====Radiotherapy==== | |
− | + | *[[External_beam_radiotherapy|Total body irradiation (TBI)]] by the following risk-based criteria: | |
− | + | **Arm D Only: 1,200 cGy in 8 once daily fractions to start on day 50 of DI | |
− | * | + | **CNS3 T-ALL: 1,800 cGy in 10 once daily fractions to start on day 50 of DI |
− | *CNS3 T-ALL: | + | '''63-day course''' |
− | + | </div></div><br> | |
− | '''63 | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Maintenance, Arms B and D {{#subobject:9d711b|Variant=1}}=== | |
− | == | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | |||
− | # | ||
− | |||
− | |||
− | ===Maintenance | ||
− | Arms B and D | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) on days 1, 57 |
− | + | *[[Mercaptopurine (6-MP)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 28, 36 to 84 | |
− | *[[Mercaptopurine (6-MP)]] 75 mg/m<sup>2</sup> | + | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> PO on days 8, 15, 22, 36, 43, 50, 57, 64, 71, 78 |
− | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> | + | **No dose escalation recommended for the first maintenance cycle |
− | **No dose escalation recommended for the first maintenance cycle | + | **Thereafter, for ANC at least 1500 μL on 3 CBCs done over 6 weeks or 2 monthly CBCs, increase dose of methotrexate or mercaptopurine by 25% |
− | **Thereafter, for ANC | + | *[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV over 60 minutes once per day on days 29 to 33 |
− | *[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV over 60 minutes once per day on days 29 | + | **DO NOT Administer with other Chemotherapy agents |
− | **DO NOT Administer with other Chemotherapy agents | + | ====Glucocorticoid therapy==== |
− | + | *[[Prednisone (Sterapred)]] 20 mg/m<sup>2</sup> PO twice per day on days 1 to 5 and 57 to 61 (Total of 40 mg/m<sup>2</sup>/day, divided twice per day) | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on day 1 | |
− | *[[Methotrexate (MTX)]] IT once on day 1 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | |||
Repeat above cycle for a total of 3 cycles. | Repeat above cycle for a total of 3 cycles. | ||
− | + | '''3 cycles''' | |
− | '''3 | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | == | + | ===Maintenance, continuation after cycle 3 (Arms B and D) {{#subobject:9d711b|Variant=1}}=== |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | # | ||
− | |||
− | |||
− | === | ||
− | Arms B and D | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 29, 57 |
− | + | *[[Mercaptopurine (6-MP)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 84 | |
− | *[[Mercaptopurine (6-MP)]] 75 mg/m<sup>2</sup> | + | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> PO once per day on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 |
− | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> | + | **No dose escalation recommended for the first maintenance cycle |
− | **No dose escalation recommended for the first maintenance cycle | + | **Thereafter, for ANC at least 1500 μL on 3 CBCs done over 6 weeks or 2 monthly CBCs, increase dose of methotrexate or mercaptopurine by 25% |
− | **Thereafter, for ANC | + | ====Glucocorticoid therapy==== |
− | + | *[[Prednisone (Sterapred)]] 20 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 29 to 33, 57 to 61 (Total of 40 mg/m<sup>2</sup>/day, divided twice per day) | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on day 1 | |
− | *[[Methotrexate (MTX)]] IT once on day 1 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | |||
====Duration==== | ====Duration==== | ||
*Girls T-ALL: Continue repeating 12 week cycles of maintenance therapy II until the total duration of therapy is two years from the start of Interim Maintenance (~ Week 121) | *Girls T-ALL: Continue repeating 12 week cycles of maintenance therapy II until the total duration of therapy is two years from the start of Interim Maintenance (~ Week 121) | ||
*Boys T-ALL: Continue to repeat 12 week cycles of Maintenance therapy II until the total duration of therapy is three years from the start of Interim Maintenance (~ Week 173). | *Boys T-ALL: Continue to repeat 12 week cycles of Maintenance therapy II until the total duration of therapy is three years from the start of Interim Maintenance (~ Week 173). | ||
*T-NHL patients (regardless of gender): Continue to repeat 12 week cycles of maintenance therapy II until the total duration reaches two years from the start of Interim Maintenance (~ Week 121) | *T-NHL patients (regardless of gender): Continue to repeat 12 week cycles of maintenance therapy II until the total duration reaches two years from the start of Interim Maintenance (~ Week 121) | ||
− | + | '''84-day course''' | |
− | '''84 | + | </div></div></div> |
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | =COG AALL1231 Arm A= | + | ==COG AALL1231 Protocol Arm A== |
− | == | + | <div class="toccolours" style="background-color:#c8a2c8"> |
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
− | + | !style="width: 20%"|Study | |
− | + | !style="width: 20%"|Dates of enrollment | |
− | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | |
− | {| class="wikitable sortable" style="width: | + | !style="width: 20%"|Comparator |
− | !style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
− | !style="width: | ||
− | !style="width: | ||
|- | |- | ||
− | |(COG AALL1231) | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9242409/ Teachey et al. 2022 (COG AALL1231)] |
− | |2014- | + | |2014-2017 |
− | |style="background-color:# | + | | style="background-color:#1a9851" |Phase 3 (C) |
+ | |COG AALL1231 Protocol Arm B (with bortezomib) | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | ||
|- | |- | ||
|} | |} | ||
− | ''Note: | + | ''Note: Per the protocol, it is intended only for patients greater than 1 and less than 31 years of age.'' |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
+ | ===Induction {{#subobject:61171f|Variant=1}}=== | ||
+ | All T-ALL and T-LLy patients | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours once on day 4, 18 |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 |
− | + | *[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV over 1 to 15 minutes once per day on days 1, 8, 15, 22 | |
− | *[[ | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 3 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 28 (DO NOT TAPER) | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Cytarabine (Ara-C)]] IT once on day 1 or at the time of diagnostic lumbar puncture (if within 72 hours of protocol initiation) | |
− | *[[Cytarabine (Ara-C)]] IT once on day 1 or at the time of diagnostic lumbar puncture (if within 72 hours of protocol initiation) | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Initial Dose | ! style="width: 25%" |Initial Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|30 mg | |30 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|50 mg | |50 mg | ||
|- | |- | ||
− | | | + | |3.00 or older |
|70 mg | |70 mg | ||
|} | |} | ||
− | + | *[[Methotrexate (MTX)]] IT once per day on days 8, 29 | |
− | *[[Methotrexate (MTX)]] IT once per day on days 8 | + | ====CNS treatment==== |
− | **CNS3 patients also receive [[Methotrexate (MTX)]] IT on days 15 | + | **CNS3 patients also receive [[Methotrexate (MTX)]] IT on days 15, 22 |
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | </div></div><br> | |
− | == | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Consolidation {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | # | ||
− | # | ||
− | |||
− | == | ||
− | |||
All T-ALL and T-LLy Patients | All T-ALL and T-LLy Patients | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | + | ====Chemotherapy==== | |
− | + | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day over 30 to 60 minutes on days 1, 29 | |
− | + | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> IV over 1 to 30 minutes or SC once per day on days 1 to 4, 8 to 11, 29 to 32, 36 to 39 | |
− | + | *[[Mercaptopurine (6-MP)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 14, 29 to 42 | |
− | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 15, 43 | |
− | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days on days 15, 22, 43, 50 | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once per day on days 1, 8, 15, 22 | |
− | + | **CNS3 patients and CNS3 T-LLy: Omit days 15, 22 | |
− | |||
− | |||
− | |||
− | |||
− | ===Chemotherapy=== | ||
− | *[[Cyclophosphamide (Cytoxan)]] | ||
− | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> | ||
− | *[[Mercaptopurine (6-MP)]] 60 mg/m<sup>2</sup> | ||
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> ( | ||
− | |||
− | ===CNS prophylaxis=== | ||
− | *[[Methotrexate (MTX)]] IT once per day on days 1, 8, 15 | ||
− | **CNS3 patients and CNS3 T-LLy: Omit days 15 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | '''56 | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Interim Maintenance, SR patients, with CMTX {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | |||
− | ===Interim Maintenance with CMTX=== | ||
− | |||
SR Patients Receive After Consolidation | SR Patients Receive After Consolidation | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 | + | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 |
− | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose | + | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 2, 22 |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once per day on days 1 & 31 | |
− | |||
− | *[[Methotrexate (MTX)]] IT once on days 1 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | + | </div></div><br> | |
− | '''56 | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Delayed Intensification {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | ===Delayed Intensification=== | ||
− | |||
All T-ALL and T-LLy Patients | All T-ALL and T-LLy Patients | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) on days 1, 8, 15, 43, 50 |
− | + | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once on day 29 | |
− | *[[Cyclophosphamide (Cytoxan)]] | + | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39 |
− | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> | + | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV push or infusion over 1 to 15 minutes once per day on days 1, 8, 15 |
− | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours on day 4, 18, 43 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> PO once per day on days 29 to 42 |
− | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 7, 15 to 21 (10 mg/m<sup>2</sup>/day, divided twice per day) | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once per day on days 1, 29, 36 | |
− | *[[Methotrexate (MTX)]] IT once on days 1, 29, | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | + | </div></div><br> | |
− | '''56 | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Delayed Intensification, IR patients {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | |||
− | |||
− | ===Delayed Intensification=== | ||
− | |||
All T-ALL and T-LLy Patients | All T-ALL and T-LLy Patients | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (max dose 2 mg) on days 1, 8, 15, 43, 50 |
− | + | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once on day 29 | |
− | *[[Cyclophosphamide (Cytoxan)]] | + | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39 |
− | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> | + | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV push or infusion over 1 to 15 minutes once per day on days 1, 8, 15 |
− | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours on day 4, 18, 43 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> PO once per day on days 29 to 42 |
− | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 7, 15 to 21 (10 mg/m<sup>2</sup>/day, divided twice per day) | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once per day on days 1, 29, 36 | |
− | *[[Methotrexate (MTX)]] IT once on days 1, 29, | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | + | </div></div><br> | |
− | '''56 | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Interim Maintenance, #1 with HDMTX - ALL IR Patients {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | ===Interim Maintenance #1 with HDMTX - ALL IR Patients=== | ||
− | |||
SR and VHR T-ALL and T-LLy DO NOT RECEIVE | SR and VHR T-ALL and T-LLy DO NOT RECEIVE | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 15, 29, | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 15, 29, 43 |
− | *[[Mercaptopurine (6-MP)]] 25 mg/m<sup>2</sup> | + | *[[Mercaptopurine (6-MP)]] 25 mg/m<sup>2</sup> PO once per day on days 1 to 56. |
− | *High Dose [[Methotrexate (MTX)]] 5,000 mg/m<sup>2</sup> IV over 24 hours on days 1, 15, 29, | + | *High Dose [[Methotrexate (MTX)]] 5,000 mg/m<sup>2</sup> IV over 24 hours on days 1, 15, 29, 43. |
− | **Methotrexate 500 mg/m<sup>2</sup> IV infused over 30 minutes | + | **[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV infused over 30 minutes, then 4500 mg/m<sup>2</sup> given by continuous IV infusion over 23.5 hours |
− | *[[Folinic acid | + | ====Supportive therapy==== |
− | + | *[[Leucovorin (Folinic acid)]] 15 mg/m<sup>2</sup> x a minimum of 3 doses PO or IV (given at 42, 48, and 54 hours after the START of high dose methotrexate infusion) on days 3, 4, 17, 18, 31, 32, 45, 46 | |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once per day on days 1, 29, 36 | |
− | *[[Methotrexate (MTX)]] IT once on days 1, 29, | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | '''56 | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Interim Maintenance, #2 with CMTX - ALL IR Patients {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | ===Interim Maintenance #2 with CMTX - ALL IR Patients=== | ||
− | |||
IR T-ALL and T-LLy Patients receive this after DI as IM#2 | IR T-ALL and T-LLy Patients receive this after DI as IM#2 | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 | + | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 |
− | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose | + | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 2, 22 |
− | + | ====CNS prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once per day on days 1 & 31 | |
− | |||
− | *[[Methotrexate (MTX)]] IT once on days 1 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
+ | '''56-day course''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
− | + | ===Intensification, Block 1 (VHR patients) {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | === | ||
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | |||
− | |||
− | |||
− | |||
VHR Patients receive immediately after consolidation | VHR Patients receive immediately after consolidation | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *High Dose [[Methotrexate (MTX)]] 5000 mg/m<sup>2</sup> IV over 24 hours on day 1 ONLY. | |
− | *High Dose [[Methotrexate (MTX)]] | + | **[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV infused over 30 minutes, then 4500 mg/m<sup>2</sup> given by continuous IV infusion over 23.5 hours |
− | **Methotrexate 500 mg/m<sup>2</sup> IV infused over 30 minutes | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) on days 1, 6 |
− | + | *[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> every 12 hours IV over 1 to 6 hours x 5 doses on days 2 to 4 | |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *High Dose [[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> every 12 hours IV over 3 hours x 2 doses on day 5 |
− | *[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV over 1 to 2 hours on day 6 |
− | *High Dose [[Cytarabine (Ara-C)]] | + | ** Administer 3 hours after completion of the second high dose [[Cytarabine (Ara-C)]] infusion |
− | *[[Pegaspargase (Oncaspar)]] | + | ====Glucocorticoid therapy==== |
− | ** Administer 3 hours after completion of the second high dose Cytarabine infusion | + | *[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 5 (20 mg/m<sup>2</sup>/day, divided twice per day) |
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg | + | ====Supportive therapy==== |
− | **Alternative: [[Pegfilgrastim (Neulasta)]] 100 mcg/kg ( | + | *[[Leucovorin (Folinic acid)]] 15 mg/m<sup>2</sup> x a minimum of 3 doses PO or IV (given at 42, 48, and 54 hours after the START of high dose methotrexate infusion) on days 3, 4 |
− | ==== | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC or IV once per day beginning on day 7 and until WBC count more than 3 x 10<sup>9</sup>/L |
− | + | **Alternative: [[Pegfilgrastim (Neulasta)]] 100 mcg/kg (Maximum dose of 6 mg) SC once during the 7 to 11th day | |
− | + | ====CNS prophylaxis, Triple Intrathecal Therapy==== | |
− | + | *[[Methotrexate (MTX)]] by the following age-based criteria: | |
− | *1 | + | **1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | **2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | ** | + | **9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | *2 to | + | *[[Hydrocortisone (Cortef)]] by the following age-based criteria: |
− | + | **1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | * | + | **2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | *3 to | + | **9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | *[[Cytarabine (Ara-C)]] by the following age-based criteria: | |
− | ** | + | **1 up to 2 years old: 16 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **2 up to 3 years old: 20 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | * | + | **3 up to 9 years old: 24 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | **9 years old and older: 30 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | </div></div><br> |
− | ** | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
+ | ===Intensification, Block 2 {{#subobject:61171f|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *High Dose [[Methotrexate (MTX)]] 5000 mg/m<sup>2</sup> IV over 24 hours on day 1 ONLY | |
− | *High Dose [[Methotrexate (MTX)]] | + | **[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV infused over 30 minutes, then 4500 mg/m<sup>2</sup> given by continuous IV infusion over 23.5 hours |
− | **Methotrexate 500 mg/m<sup>2</sup> IV infused over 30 minutes | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) on days 1, 6 |
− | + | *[[Ifosfamide (Ifex)]] 800 mg/m<sup>2</sup> every 12 hours IV infusion over 1 hour x 5 doses on days 2 to 4 | |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | **Start Immediately after completion of high dose [[Methotrexate (MTX)]] infusion. |
− | *[[Ifosfamide (Ifex)]] 800 mg/m<sup>2</sup> | + | *[[Daunorubicin (Cerubidine)]] 30 mg/m<sup>2</sup> IV over 1 to 15 minutes on day 5 |
− | **Start Immediately after completion of high dose | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours on day 6 |
− | + | ====Glucocorticoid therapy==== | |
− | *[[ | + | *[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 5 (20 mg/m<sup>2</sup>/day, divided twice per day) |
− | *[[ | + | ====Supportive therapy==== |
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg | + | *[[Leucovorin (Folinic acid)]] 15 mg/m<sup>2</sup> x a minimum of 3 doses PO or IV (given at 42, 48, and 54 hours after the START of high dose methotrexate infusion) on days 3, 4 |
− | **Alternative: [[Pegfilgrastim (Neulasta)]] 100 mcg/kg (Max 6 mg/dose) SC once during the 7 | + | *[[Mesna (Mesnex)]] 300 mg/m<sup>2</sup> at hour 0, 4, and 8 from the start of each ifosfamide infusion on days 2 to 4 |
− | ==== | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC or IV once per day beginning on day 7 and until WBC count more than 3 x 10<sup>9</sup>/L |
− | + | **Alternative: [[Pegfilgrastim (Neulasta)]] 100 mcg/kg (Max 6 mg/dose) SC once during the 7 to 11th day | |
− | + | ====CNS prophylaxis, Triple Intrathecal Therapy==== | |
− | + | *[[Methotrexate (MTX)]] by the following age-based criteria: | |
− | *1 | + | **1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | **2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | ** | + | **9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | *2 to | + | *[[Hydrocortisone (Cortef)]] by the following age-based criteria: |
− | + | **1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | + | **2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | * | + | **3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | *3 to | + | **9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | *[[Cytarabine (Ara-C)]] by the following age-based criteria: | |
− | ** | + | **1 up to 2 years old: 16 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **2 up to 3 years old: 20 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | * | + | **3 up to 9 years old: 24 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | **9 years old and older: 30 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | </div></div><br> |
− | ** | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Intensification, Block 3 {{#subobject:61171f|Variant=1}}=== | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | ===Intensification Block 3 | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *High Dose [[Cytarabine (Ara-C)]] 2,000 mg/m<sup>2</sup> every 12 hours IV over 3 hours x 4 doses on days 1, 2 | |
− | *High Dose [[Cytarabine (Ara-C)]] 2,000 mg/m<sup>2</sup> | + | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> every 12 hours IV over 1 to 2 hours x 5 doses on days 3 to 5 |
− | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> | + | **First dose to be given 12 hours after the start of the 4th high dose [[Cytarabine (Ara-C)]] on day 2 |
− | **First dose to be given 12 hours after the start of the 4th | + | **Infusion rate should not exceed 300 mg/m<sup>2</sup>/hour (10 mg/kg/hour) |
− | **Infusion rate should not exceed 300 mg/m<sup>2</sup>/hour (10 mg/kg/hour) | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours on day 6 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | ====Glucocorticoid therapy==== |
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg | + | *[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 5 (20 mg/m<sup>2</sup>/day, divided twice per day) |
− | **Alternative: [[Pegfilgrastim (Neulasta)]] 100 mcg/kg (Max 6 mg/dose) SC once during the 7 | + | ====Supportive therapy==== |
− | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC or IV once per day beginning on day 7 and until WBC count more than 3 x 10<sup>9</sup>/L | |
− | + | **Alternative: [[Pegfilgrastim (Neulasta)]] 100 mcg/kg (Max 6 mg/dose) SC once during the 7 to 11th day | |
− | ==== | + | ====CNS therapy, Triple Intrathecal Therapy==== |
− | + | *[[Methotrexate (MTX)]] by the following age-based criteria: | |
− | + | **1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | + | **2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | *1 | + | **3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | ** | + | **9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | *[[Hydrocortisone (Cortef)]] by the following age-based criteria: | |
− | ** | + | **1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | *2 to | + | **2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | + | **9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | * | + | *[[Cytarabine (Ara-C)]] by the following age-based criteria: |
− | *3 to | + | **1 up to 2 years old: 16 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **2 up to 3 years old: 20 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | ** | + | **3 up to 9 years old: 24 mg IT on day 1, given 2 hours after the start of HD MTX infusion |
− | + | **9 years old and older: 30 mg IT on day 1, given 2 hours after the start of HD MTX infusion | |
− | * | + | </div></div><br> |
− | ** | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | ** | + | ===Delayed Intensification {{#subobject:61171f|Variant=1}}=== |
− | ** | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | |||
− | ===Delayed Intensification=== | ||
− | |||
All T-ALL and T-LLy Patients | All T-ALL and T-LLy Patients | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) on days 1, 8, 15, 43, 50 |
− | + | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once on day 29 | |
− | *[[Cyclophosphamide (Cytoxan)]] | + | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39 |
− | *[[Cytarabine (Ara-C)]] 75 mg/m<sup>2</sup> | + | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV push or infusion over 1 to 15 minutes once per day on days 1, 8, 15 |
− | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours on day 4, 18, 43 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> PO once per day on days 29 to 42 |
− | *[[Thioguanine (Tabloid)]] 60 mg/m<sup>2</sup> | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 7 and 15 to 21 (10 mg/m<sup>2</sup>/day, divided twice per day) | |
− | + | ====CNS therapy, prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on days 1, 29, 36 | |
− | *[[Methotrexate (MTX)]] IT once on days 1, 29, | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | + | </div></div><br> | |
− | '''56 | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Interim Maintenance, with CMTX {{#subobject:61171f|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | ===Interim Maintenance with CMTX=== | ||
− | |||
VHR Patients receive after DI | VHR Patients receive after DI | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 | + | *[[Methotrexate (MTX)]] 100 mg/m<sup>2</sup> IV once on day 1, then 150 mg/m<sup>2</sup> IV once on day 11, then 200 mg/m<sup>2</sup> IV once on day 21, then 250 mg/m<sup>2</sup> IV once on day 31, then 300 mg/m<sup>2</sup> IV once on day 41 |
− | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose | + | **If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose |
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41 |
− | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> | + | *[[Pegaspargase (Oncaspar)]] 2,500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 2, 22 |
− | + | ====CNS therapy, prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on days 1, 31 | |
− | |||
− | *[[Methotrexate (MTX)]] IT once on days 1 | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | + | '''56-day course''' | |
− | + | </div></div><br> | |
− | '''56 | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Maintenance, all patients {{#subobject:61171f|Variant=1}}=== | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
− | |||
− | |||
− | # | ||
− | |||
− | ==Maintenance | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 29, 57 |
− | + | *[[Mercaptopurine (6-MP)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 84 | |
− | *[[Mercaptopurine (6-MP)]] 75 mg/m<sup>2</sup> | + | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> once per day on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 |
− | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> | + | **Omit day 29 of the first FOUR cycles for SR T-ALL and T-LLy patients |
− | **Omit day 29 of the first FOUR cycles for SR T-ALL and T-LLy patients | + | **Omit day 29 of the first TWO cycles for IR T-ALL and T-LLy patients |
− | **Omit day 29 of the first TWO cycles for IR T-ALL and T-LLy patients | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 3 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 5, 29 to 33, 57 to 61 (6 mg/m<sup>2</sup>/day, divided twice per day) | |
− | + | ====CNS therapy, prophylaxis==== | |
− | + | *[[Methotrexate (MTX)]] IT once on days 1 | |
− | *[[Methotrexate (MTX)]] IT once on days 1 | + | **Also on day 29 of the first FOUR cycles for SR patients |
− | **Also on day 29 of the first FOUR cycles for SR patients | + | **Also on day 29 of the first TWO cycles for IR patients |
− | **Also on day 29 of the first TWO cycles for IR patients | ||
− | |||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
− | ! style="width: 25%" |Age | + | ! style="width: 25%" |Age in years, rounded to the nearest hundredth |
! style="width: 25%" |Dose | ! style="width: 25%" |Dose | ||
|- | |- | ||
− | |1 | + | |1.00 to 1.99 |
|8 mg | |8 mg | ||
|- | |- | ||
− | |2 | + | |2.00 to 2.99 |
|10 mg | |10 mg | ||
|- | |- | ||
− | |3 | + | |3.00 to 8.99 |
|12 mg | |12 mg | ||
|- | |- | ||
− | | | + | |9.00 or older |
|15 mg | |15 mg | ||
|} | |} | ||
− | |||
====Radiotherapy==== | ====Radiotherapy==== | ||
− | + | *[[External_beam_radiotherapy|Total body irradiation (TBI)]] during the first cycle of maintenance, by the following histology- and risk-based criteria: | |
− | + | **T-ALL AND CNS1 VHR: 1200 cGy | |
− | + | **T-ALL AND CNS2 VHR: 1200 cGy | |
− | *T-ALL | + | **T-ALL AND CNS3 IR: 1800 cGy |
− | + | **T-ALL AND CNS3 VHR: 1800 cGy | |
− | **CNS2 VHR: | + | **T-LLy AND CNS3 IR: 1800 cGy |
− | **CNS3 IR: | + | **T-LLy AND CNS3 VHR: 1800 cGy |
− | **CNS3 VHR: | + | '''Duration of therapy:''' |
− | *T-LLy | ||
− | |||
− | **CNS3 VHR: | ||
− | |||
− | |||
*SR and IR T-ALL Girls: repeat 12 week cycles of maintenance for a total duration of 2 years from Interim Maintenance start. | *SR and IR T-ALL Girls: repeat 12 week cycles of maintenance for a total duration of 2 years from Interim Maintenance start. | ||
*VHR T-ALL Girls: Repeat 12 week cycles of maintenance for a total duration of 2 years from Intensification Block 1 start. | *VHR T-ALL Girls: Repeat 12 week cycles of maintenance for a total duration of 2 years from Intensification Block 1 start. | ||
Line 1,131: | Line 729: | ||
*VHR T-ALL Boys: Repeat 12 week cycles of maintenance for a total duration of 3 years from Intensification Block 1 start. | *VHR T-ALL Boys: Repeat 12 week cycles of maintenance for a total duration of 3 years from Intensification Block 1 start. | ||
*T-LLy regardless of gender: repeat 12 week cycles of maintenance for a total duration of 2 years from Interim Maintenance start. | *T-LLy regardless of gender: repeat 12 week cycles of maintenance for a total duration of 2 years from Interim Maintenance start. | ||
+ | </div></div></div> | ||
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | # '''COG AALL1231:''' NCT02112916 | + | # '''COG AALL1231:''' Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. Epub 2022 Mar 10. [https://doi.org/10.1200/jco.21.02678 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9242409/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35271306/ PubMed] [https://clinicaltrials.gov/study/NCT02112916 NCT02112916] |
=Pre-phase= | =Pre-phase= | ||
==Methylprednisolone monotherapy {{#subobject:5gh1bb|Regimen=1}}== | ==Methylprednisolone monotherapy {{#subobject:5gh1bb|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:88fgh7|Variant=1}}=== | ===Regimen {{#subobject:88fgh7|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/s1470-2045(15)00363-0 Place et al. 2015 (DFCI 05-001)] | |[https://doi.org/10.1016/s1470-2045(15)00363-0 Place et al. 2015 (DFCI 05-001)] | ||
|2005-2011 | |2005-2011 | ||
− | | style="background-color:#91cf61" |Non-randomized | + | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT |
|- | |- | ||
− | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8369809/ Burns et al. 2020 (DFCI 11-001)] |
|2012-2015 | |2012-2015 | ||
− | | style="background-color:#91cf61" |Non-randomized | + | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT |
|- | |- | ||
|} | |} | ||
''Note: Burns et al. 2020 is both an update of DFCI 05-001 and the primary publication of DFCI 11-001.'' | ''Note: Burns et al. 2020 is both an update of DFCI 05-001 and the primary publication of DFCI 11-001.'' | ||
− | ==== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
+ | ====Glucocorticoid therapy==== | ||
*[[Methylprednisolone (Solumedrol)]] 8 mg/m<sup>2</sup> IV three times per day on days 1 to 3 | *[[Methylprednisolone (Solumedrol)]] 8 mg/m<sup>2</sup> IV three times per day on days 1 to 3 | ||
− | |||
'''3-day course''' | '''3-day course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *DFCI 05-001: Doxorubicin, L- | + | *DFCI 05-001: [[#Doxorubicin.2C_L-Asparaginase.2C_Methotrexate.2C_Vincristine.2C_Methylprednisolone_888|Doxorubicin, L-asparaginase, Methotrexate, Vincristine, Methylprednisolone]] versus [[#Doxorubicin.2C_Methotrexate.2C_Pegaspargase.2C_Vincristine.2C_Methylprednisolone|Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone]] induction |
− | *DFCI 11-001: Calaspargase, Doxorubicin, Methotrexate, Vincristine, Methylprednisolone | + | *DFCI 11-001: [[#Calaspargase.2C_Doxorubicin.2C_Methotrexate.2C_Vincristine.2C_Methylprednisolone_999|Calaspargase, Doxorubicin, Methotrexate, Vincristine, Methylprednisolone]] versus [[#Doxorubicin.2C_Methotrexate.2C_Pegaspargase.2C_Vincristine.2C_Methylprednisolone|Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone]] induction |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''DFCI 05-001:''' Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. Epub 2015 Nov 6. [https://doi.org/10.1016/s1470-2045(15)00363-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26549586/ PubMed] NCT00400946 | + | # '''DFCI 05-001:''' Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. Epub 2015 Nov 6. [https://doi.org/10.1016/s1470-2045(15)00363-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26549586/ PubMed] [https://clinicaltrials.gov/study/NCT00400946 NCT00400946] |
− | ## '''Pooled update:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] ''' | + | ## '''Pooled update:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8369809/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33026184/ PubMed] |
− | # '''DFCI 11-001:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] ''' | + | # '''DFCI 11-001:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8369809/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33026184/ PubMed] [https://clinicaltrials.gov/study/NCT01574274 NCT01574274] |
## '''Update:''' Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. Epub 2021 Jul 6. [https://doi.org/10.1200/jco.20.03692 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34228505/ PubMed] | ## '''Update:''' Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. Epub 2021 Jul 6. [https://doi.org/10.1200/jco.20.03692 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34228505/ PubMed] | ||
=Upfront induction therapy= | =Upfront induction therapy= | ||
− | ==Daunorubicin, | + | ==Daunorubicin, L-Asparaginase, Vincristine, Dexamethasone {{#subobject:51la7b|Regimen=1}}== |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen, modified ABFM {{#subobject:8cn320|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s2352-3026(23)00072-8 Sato et al. 2023 (ALL-T11)] | ||
+ | |2011-12-01 to 2017-11-30 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
− | |||
|} | |} | ||
+ | ''Note: Day counts included a 7-day pre-phase, not shown here.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Daunorubicin (Cerubidine)]] 30 mg/m<sup>2</sup> IV once per day on days 8, 15, 22, 29 | ||
+ | *[[Asparaginase (Elspar)]] 5000 units/m<sup>2</sup> IM or IV once per day on days 12, 15, 18, 21, 24, 27, 30, 33 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8, 15, 22, 29 | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] by the following age-based criteria: | ||
+ | **Younger than 10 years old: 10 mg/m<sup>2</sup>/day PO on days 8 to 28 | ||
+ | **10 years old or older: 10 mg/m<sup>2</sup>/day PO on days 8 to 14, 22 to 28 | ||
+ | ====CNS therapy, prophylaxis==== | ||
+ | *[[Cytarabine (Ara-C)]] by the following age-based criteria: | ||
+ | **Younger than 1 year old: 16 mg IT once per day on days 12 & 33 | ||
+ | **1 to 1.99 years old: 20 mg IT once per day on days 12 & 33 | ||
+ | **2 to 2.99 years old: 26 mg IT once per day on days 12 & 33 | ||
+ | **3 years old or older: 30 mg IT once per day on days 12 & 33 | ||
+ | *[[Methotrexate (MTX)]] by the following age-based criteria: | ||
+ | **Younger than 1 year old: 6 mg IT once per day on days 12 & 33 | ||
+ | **1 to 1.99 years old: 8 mg IT once per day on days 12 & 33 | ||
+ | **2 to 2.99 years old: 10 mg IT once per day on days 12 & 33 | ||
+ | **3 years old or older: 12 mg IT once per day on days 12 & 33 | ||
+ | *[[Prednisolone (Millipred) by the following age-based criteria | ||
+ | **Younger than 1 year old: 4 mg IT once per day on days 12 & 33 | ||
+ | **1 to 1.99 years old: 6 mg IT once per day on days 12 & 33 | ||
+ | **2 to 2.99 years old: 8 mg IT once per day on days 12 & 33 | ||
+ | **3 years old or older: 10 mg IT once per day on days 12 & 33 | ||
+ | '''4-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
+ | ====Subsequent treatment==== | ||
+ | *See paper for details | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''ALL-T11:''' Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Lancet Haematol. 2023 Jun;10(6):e419-e432. Epub 2023 May 8. Erratum in: Lancet Haematol. 2023 Jun;10(6):e399. [https://doi.org/10.1016/s2352-3026(23)00072-8 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37167992/ PubMed] jRCTs041180145 | ||
+ | |||
+ | ==Daunorubicin, Pegaspargase, Vincristine, Dexamethasone {{#subobject:516f7b|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen, modified ABFM {{#subobject:88f520|Variant=1}}=== | ===Regimen, modified ABFM {{#subobject:88f520|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(12)70600-9 Vora et al. 2013 (UKALL 2003)] |
|2003-2011 | |2003-2011 | ||
− | | style="background-color:#91cf61" |Non-randomized | + | | style="background-color:#91cf61" |Non-randomized part of phase 2 RCT |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV over 1 to 15 minutes once per day on days 1, 8, 15, 22 | *[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV over 1 to 15 minutes once per day on days 1, 8, 15, 22 | ||
*[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 4 & 18 | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 4 & 18 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 3 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 28 | *[[Dexamethasone (Decadron)]] 3 mg/m<sup>2</sup> IV or PO twice per day on days 1 to 28 | ||
− | + | ====CNS therapy, prophylaxis==== | |
− | ====CNS prophylaxis==== | + | *[[Cytarabine (Ara-C)]] by the following age-based criteria: |
− | *[[Cytarabine (Ara-C)]] | + | **1 to 1.99 years old: 30 mg IT once on day 1 |
− | ** | + | **2 to 2.99 years old: 50 mg IT once on day 1 |
− | ** | + | **3 years old or older: 70 mg IT once on day 1 |
− | ** | + | *[[Methotrexate (MTX)]] by the following age-based criteria: |
− | *[[Methotrexate (MTX)]] | + | **1 to 1.99 years old: 8 mg IT once per day on days 8 & 29 |
− | ** | + | **2 to 2.99 years old: 10 mg IT once per day on days 8 & 29 |
− | ** | + | **3 to 8.99 years old: 12 mg IT once per day on days 8 & 29 |
− | ** | + | **9 years old or older: 15 mg IT once per day on days 8 & 29 |
− | ** | ||
− | |||
'''4-week course''' | '''4-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, cytarabine, mercaptopurine, pegaspargase, vincristine | + | *[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, cytarabine, mercaptopurine, pegaspargase, vincristine]] consolidation |
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''UKALL 2003:''' Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. [https:// | + | # '''UKALL 2003:''' Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. Epub 2013 Feb 7. [https://doi.org/10.1016/S1470-2045(12)70600-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23395119/ PubMed] ISRCTN07355119 |
==Daunorubicin, Pegaspargase, Vincristine, Prednisone {{#subobject:a39331|Regimen=1}}== | ==Daunorubicin, Pegaspargase, Vincristine, Prednisone {{#subobject:a39331|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:1511c2|Variant=1}}=== | ===Regimen {{#subobject:1511c2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ Winter et al. 2015 (COG AALL0434)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ Winter et al. 2015 (COG AALL0434)] | ||
|2007-2014 | |2007-2014 | ||
− | |style="background-color:#91cf61"|Non-randomized | + | |style="background-color:#91cf61"|Non-randomized part of phase 3 RCT |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | *[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
*[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV once on day 5 +/- 1 day | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV once on day 5 +/- 1 day | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Prednisone (Sterapred)]] 30 mg/m<sup>2</sup> PO twice per day on days 1 to 28 | *[[Prednisone (Sterapred)]] 30 mg/m<sup>2</sup> PO twice per day on days 1 to 28 | ||
− | |||
'''4-week course''' | '''4-week course''' | ||
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] | *[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | |||
==DOLP {{#subobject:3c9897|Regimen=1}}== | ==DOLP {{#subobject:3c9897|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
DOLP: '''<u>D</u>'''aunorubicin, '''<u>O</u>'''ncovin (Vincristine), '''<u>L</u>'''-Asparaginase, '''<u>P</u>'''rednisone | DOLP: '''<u>D</u>'''aunorubicin, '''<u>O</u>'''ncovin (Vincristine), '''<u>L</u>'''-Asparaginase, '''<u>P</u>'''rednisone | ||
<br>DVPA: '''<u>D</u>'''aunorubicin, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone, '''<u>A</u>'''sparaginase | <br>DVPA: '''<u>D</u>'''aunorubicin, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone, '''<u>A</u>'''sparaginase | ||
− | ===Regimen | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen, BFM 76/79 Phase I {{#subobject:3fe1a2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |rowspan=2|[https:// | + | |rowspan=2|[https://doi.org/10.1016/S0140-6736(88)92596-2 Gaynon et al. 1988 (CCG-106)] |
− | |rowspan=2|1983-1984 | + | |rowspan=2|1983-05 to 1984-11 |
|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc) | |rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc) | ||
|1. Control regimen | |1. Control regimen | ||
Line 1,269: | Line 911: | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS36 | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS36 | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1002/(sici)1097-0142(19980201)82:3%3C600::aid-cncr24%3E3.0.co;2-4 Steinherz et al. 1998 (CCG-123)] |
|1983-1985 | |1983-1985 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
− | |1. LSA2-L2 & WBRT<br> 2. LSA-L2<br> 3. New York regimen | + | |1. LSA2-L2 & WBRT<br>2. LSA-L2<br>3. New York regimen |
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | ||
|- | |- | ||
|} | |} | ||
''Note: the specific days of L-asparaginase are not specified; the schedule here is similar to those of other similar protocols.'' | ''Note: the specific days of L-asparaginase are not specified; the schedule here is similar to those of other similar protocols.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | *[[Daunorubicin (Cerubidine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
*[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IM once per day on days 3, 5, 7, 10, 12, 14, 17, 19, 21 | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IM once per day on days 3, 5, 7, 10, 12, 14, 17, 19, 21 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup>/day PO on days 1 to 28, then tapered over 2 weeks | *[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup>/day PO on days 1 to 28, then tapered over 2 weeks | ||
− | |||
====CNS therapy==== | ====CNS therapy==== | ||
*[[Methotrexate (MTX)]] IT once per day on days 1, 15, 29 (dose not specified) | *[[Methotrexate (MTX)]] IT once per day on days 1, 15, 29 (dose not specified) | ||
− | |||
'''6-week course''' | '''6-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*BFM 76/79 Phase II | *BFM 76/79 Phase II | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''CCG-106:''' Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, Sather HN, Hammond GD. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet. 1988 Oct 22;2(8617):921-4. [https:// | + | # '''CCG-106:''' Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, Sather HN, Hammond GD. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet. 1988 Oct 22;2(8617):921-4. [https://doi.org/10.1016/S0140-6736(88)92596-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2902379/ PubMed] |
− | # '''CCG-123:''' Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, Bleyer WA. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer. 1998 Feb 1;82(3):600-12. [https:// | + | # '''CCG-123:''' Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, Bleyer WA. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer. 1998 Feb 1;82(3):600-12. [https://doi.org/10.1002/(sici)1097-0142(19980201)82:3%3C600::aid-cncr24%3E3.0.co;2-4 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/9452280/ PubMed] |
==Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone {{#subobject:h1gtbb|Regimen=1}}== | ==Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone {{#subobject:h1gtbb|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:hgu1h7|Variant=1}}=== | ===Regimen {{#subobject:hgu1h7|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 17%"|Study | !style="width: 17%"|Study | ||
− | !style="width: 15%"| | + | !style="width: 15%"|Dates of enrollment |
!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 17%"|Comparator | !style="width: 17%"|Comparator | ||
Line 1,311: | Line 952: | ||
|2005-2011 | |2005-2011 | ||
| style="background-color:#1a9851" |Phase 3 (E-switch-ic) | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) | ||
− | |Doxorubicin, L- | + | |[[#Doxorubicin.2C_L-Asparaginase.2C_Methotrexate.2C_Vincristine.2C_Methylprednisolone_888|Doxorubicin, L-asparaginase, Methotrexate, Vincristine, Methylprednisolone]] |
| style="background-color:#ffffbf" |Did not meet secondary endpoint of DFS | | style="background-color:#ffffbf" |Did not meet secondary endpoint of DFS | ||
| style="background-color:#1a9850" |Less anxiety | | style="background-color:#1a9850" |Less anxiety | ||
|- | |- | ||
− | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8369809/ Burns et al. 2020 (DFCI 11-001)] |
|2012-2015 | |2012-2015 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
− | |Calaspargase, Doxorubicin, Methotrexate, Vincristine, Methylprednisolone | + | |[[#Calaspargase.2C_Doxorubicin.2C_Methotrexate.2C_Vincristine.2C_Methylprednisolone_999|Calaspargase, Doxorubicin, Methotrexate, Vincristine, Methylprednisolone]] |
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
| | | | ||
Line 1,324: | Line 965: | ||
|} | |} | ||
''Note: Burns et al. 2020 is both an update of DFCI 05-001 and the primary publication of DFCI 11-001. Day numbering takes into account the pre-phase.'' | ''Note: Burns et al. 2020 is both an update of DFCI 05-001 and the primary publication of DFCI 11-001. Day numbering takes into account the pre-phase.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#Methylprednisolone_monotherapy|Methylprednisolone pre-phase | + | *[[#Methylprednisolone_monotherapy|Methylprednisolone]] pre-phase |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 4 & 5 | *[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 4 & 5 | ||
Line 1,331: | Line 975: | ||
*[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV once on day 7 | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV once on day 7 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 4, 11, 18, 25 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 4, 11, 18, 25 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Methylprednisolone (Solumedrol)]] 8 mg/m<sup>2</sup> IV three times per day on days 4 to 32 | *[[Methylprednisolone (Solumedrol)]] 8 mg/m<sup>2</sup> IV three times per day on days 4 to 32 | ||
− | ====Supportive | + | ====Supportive therapy==== |
*[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> IV once per day on days 4 & 5 | *[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> IV once per day on days 4 & 5 | ||
'''28-day course''' | '''28-day course''' | ||
− | ====CNS prophylaxis==== | + | ====CNS therapy, prophylaxis==== |
*[[Cytarabine (Ara-C)]] IT once per day on days 1 & 18 | *[[Cytarabine (Ara-C)]] IT once per day on days 1 & 18 | ||
**Day 18 dose is admixed with MTX and HC | **Day 18 dose is admixed with MTX and HC | ||
Line 1,341: | Line 986: | ||
**Day 18 dose is admixed with Ara-C and HC | **Day 18 dose is admixed with Ara-C and HC | ||
*[[Hydrocortisone (Cortef)]] IT once on day 18, admixed with Ara-C and MTX | *[[Hydrocortisone (Cortef)]] IT once on day 18, admixed with Ara-C and MTX | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *[[#Doxorubicin.2C_Mercaptopurine.2C_Methotrexate. | + | *[[#Doxorubicin.2C_Mercaptopurine.2C_Methotrexate.2C_Vincristine|Doxorubicin, Mercaptopurine, Methotrexate, Vincristine]] consolidation (IA) |
+ | </div></div> | ||
+ | |||
===References=== | ===References=== | ||
− | # '''DFCI 05-001:''' Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. Epub 2015 Nov 6. [https://doi.org/10.1016/s1470-2045(15)00363-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26549586/ PubMed] NCT00400946 | + | # '''DFCI 05-001:''' Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. Epub 2015 Nov 6. [https://doi.org/10.1016/s1470-2045(15)00363-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26549586/ PubMed] [https://clinicaltrials.gov/study/NCT00400946 NCT00400946] |
− | ## '''Pooled update:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] ''' | + | ## '''Pooled update:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8369809/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33026184/ PubMed] |
− | # '''DFCI 11-001:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] ''' | + | # '''DFCI 11-001:''' Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. [https://doi.org/10.1002/pbc.28719 link to original article] '''dosing details in supplement have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8369809/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33026184/ PubMed] [https://clinicaltrials.gov/study/NCT01574274 NCT01574274] |
## '''Update:''' Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. Epub 2021 Jul 6. [https://doi.org/10.1200/jco.20.03692 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34228505/ PubMed] | ## '''Update:''' Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. Epub 2021 Jul 6. [https://doi.org/10.1200/jco.20.03692 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34228505/ PubMed] | ||
− | |||
=Consolidation after upfront therapy= | =Consolidation after upfront therapy= | ||
− | |||
==Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine {{#subobject:ae17db|Regimen=1}}== | ==Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine {{#subobject:ae17db|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:9d711b|Variant=1}}=== | ===Regimen {{#subobject:9d711b|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 17%"|Study | !style="width: 17%"|Study | ||
− | !style="width: 15%"| | + | !style="width: 15%"|Dates of enrollment |
!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 17%"|Comparator | !style="width: 17%"|Comparator | ||
Line 1,367: | Line 1,011: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ Winter et al. 2015 (COG AALL0434)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ Winter et al. 2015 (COG AALL0434)] | ||
|2007-2014 | |2007-2014 | ||
− | |style="background-color:#1a9851"|Phase 3 (E-esc) | + | |style="background-color:#1a9851"|Phase 3 (E-RT-esc) |
|[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] | |[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] | ||
− | |style="background-color:# | + | | style="background-color:#91cf60" |Seems to have superior DFS<sup>1</sup> (primary endpoint) |
|style="background-color:#ffffbf"|Similar toxicity | |style="background-color:#ffffbf"|Similar toxicity | ||
|- | |- | ||
|} | |} | ||
+ | ''<sup>1</sup>Reported efficacy is based on the 2020 update.''<br> | ||
''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Prednisone|Daunorubicin, Pegaspargase, Vincristine, Prednisone | + | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Prednisone|Daunorubicin, Pegaspargase, Vincristine, Prednisone]] induction |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day on days 8 & 50 | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day on days 8 & 50 | ||
Line 1,383: | Line 1,031: | ||
*[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IM once per day on days 22 & 64 | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IM once per day on days 22 & 64 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 22, 64, 71 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 22, 64, 71 | ||
− | + | ====CNS therapy, prophylaxis==== | |
− | ====CNS prophylaxis==== | ||
*[[Methotrexate (MTX)]] (dose not specified) IT on days 15, 22, 57, 64 | *[[Methotrexate (MTX)]] (dose not specified) IT on days 15, 22, 57, 64 | ||
*[[External_beam_radiotherapy|Whole-brain irradiation]] in some arms (see paper for details) | *[[External_beam_radiotherapy|Whole-brain irradiation]] in some arms (see paper for details) | ||
− | |||
'''71-day course''' | '''71-day course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Interim maintenance; see paper for details | *Interim maintenance; see paper for details | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | |||
==Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine {{#subobject:9e619a|Regimen=1}}== | ==Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine {{#subobject:9e619a|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen variant #1 {{#subobject:9d3523|Variant=1}}=== | ===Regimen variant #1 {{#subobject:9d3523|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 17%"|Study | !style="width: 17%"|Study | ||
− | !style="width: 15%"| | + | !style="width: 15%"|Dates of enrollment |
!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 17%"|Comparator | !style="width: 17%"|Comparator | ||
Line 1,420: | Line 1,064: | ||
|} | |} | ||
''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ''Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Prednisone|Daunorubicin, Pegaspargase, Vincristine, Prednisone | + | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Prednisone|Daunorubicin, Pegaspargase, Vincristine, Prednisone]] induction |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day on days 8 & 50 | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day on days 8 & 50 | ||
Line 1,428: | Line 1,075: | ||
*[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IM once per day on days 22 & 64 | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IM once per day on days 22 & 64 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 22, 64, 71 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 22, 64, 71 | ||
− | + | ====CNS therapy, prophylaxis==== | |
− | ====CNS prophylaxis==== | ||
*[[Methotrexate (MTX)]] (dose not specified) IT on days 15, 22, 57, 64 | *[[Methotrexate (MTX)]] (dose not specified) IT on days 15, 22, 57, 64 | ||
*[[External_beam_radiotherapy|Whole-brain irradiation]] in some arms (see paper for details) | *[[External_beam_radiotherapy|Whole-brain irradiation]] in some arms (see paper for details) | ||
− | |||
'''71-day course''' | '''71-day course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Interim maintenance; see paper for details | *Interim maintenance; see paper for details | ||
− | + | </div></div><br> | |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen variant #2 {{#subobject:61171f|Variant=1}}=== | ===Regimen variant #2 {{#subobject:61171f|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |(COG AALL1231) | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9242409/ Teachey et al. 2022 (COG AALL1231)] |
− | |2014- | + | |2014-2017 |
− | |style="background-color:#91cf61"|Non-randomized | + | |style="background-color:#91cf61"|Non-randomized part of phase 3 RCT |
|- | |- | ||
|} | |} | ||
− | ''Note: | + | ''Note: Per the protocol, it is intended only for patients greater than 1 and less than 31 years of age.'' |
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Dexamethasone|Daunorubicin, pegaspargase, vincristine, dexamethasone | + | *[[#Daunorubicin.2C_Pegaspargase.2C_Vincristine.2C_Dexamethasone|Daunorubicin, pegaspargase, vincristine, dexamethasone]] induction |
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 29 | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 29 | ||
Line 1,458: | Line 1,109: | ||
*[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 15 & 43 | *[[Pegaspargase (Oncaspar)]] 2500 units/m<sup>2</sup> IV over 1 to 2 hours once per day on days 15 & 43 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 15, 22, 43, 50 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 15, 22, 43, 50 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | ||
*[[Mesna (Mesnex)]] "is not required for this dose of cyclophosphamide, but may be administered at institutional discretion." | *[[Mesna (Mesnex)]] "is not required for this dose of cyclophosphamide, but may be administered at institutional discretion." | ||
− | + | ====CNS therapy, prophylaxis==== | |
− | ====CNS prophylaxis==== | + | *[[Methotrexate (MTX)]] by the following age-based criteria, for CNS3: |
− | *[[Methotrexate (MTX)]] | + | **1 to 1.99 years old: 8 mg IT once per day on days 1 & 8 |
− | ** | + | **2 to 2.99 years old: 10 mg IT once per day on days 1 & 8 |
− | ** | + | **3 to 8.99 years old: 12 mg IT once per day on days 1 & 8 |
− | ** | + | **9 years old or older: 15 mg IT once per day on days 1 & 8 |
− | ** | ||
− | |||
'''50-day course''' | '''50-day course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*See protocol for details of treatment beyond consolidation, which is guided by MRD status obtained at the end of induction. | *See protocol for details of treatment beyond consolidation, which is guided by MRD status obtained at the end of induction. | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | # '''COG AALL1231:''' NCT02112916 | + | # '''COG AALL1231:''' Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. Epub 2022 Mar 10. [https://doi.org/10.1200/jco.21.02678 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9242409/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35271306/ PubMed] [https://clinicaltrials.gov/study/NCT02112916 NCT02112916] |
− | + | ==Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone {{#subobject:03fb9e|Regimen=1}}== | |
− | ==Doxorubicin, | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Regimen variant #1, high-dose MTX {{#subobject:9fedf6|Variant=1}}=== | |
− | |||
− | |||
− | |||
− | ===Regimen {{#subobject:9fedf6|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 1,494: | Line 1,140: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292437/ Asselin et al. 2011 (POG 9404)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292437/ Asselin et al. 2011 (POG 9404)] | ||
|1996-2001 | |1996-2001 | ||
− | | style="background-color:#1a9851" |Phase 3 ( | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
− | |[[#Doxorubicin | + | |[[#Doxorubicin.2C_Mercaptopurine.2C_Methotrexate.2C_Vincristine.2C_Prednisone|Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone]]; low-dose MTX |
− | | style="background-color:# | + | | style="background-color:#91cf60" |Seems to have superior EFS (primary endpoint) |
|- | |- | ||
|} | |} | ||
+ | ''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Doxorubicin (Adriamycin)]] | + | *[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> (maximum dose of 60 mg) IV once per day on days 1, 2, 22 |
− | *[[ | + | *[[Mercaptopurine (6-MP)]] 50 mg/m<sup>2</sup> (maximum dose of 100 mg) PO once per day on days 22 to 36 |
− | *[[ | + | *[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> (maximum dose of 80 mg) (route not specified) once on day 2, given 8 to 24 hours after doxorubicin, then 500 mg/m<sup>2</sup> (maximum dose of 1000 mg) IV over 30 minutes once on day 22, then 4500 mg/m<sup>2</sup> (maximum dose of 9000 mg) IV continuous infusion over 23.5 hours |
− | *[[Vincristine (Oncovin)]] | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV push once per week on days 1, 8, 15, 22 |
− | *[[Prednisone (Sterapred)]] | + | ====Glucocorticoid therapy==== |
− | === | + | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup>/day (maximum dose of 80 mg/day) (route not specified) on days 1 to 22 |
− | + | ====Supportive therapy==== | |
− | + | *[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> (maximum dose of 600 mg) IV once per day on days 1, 2, 22, given immediately before each dose of doxorubicin | |
− | + | '''42-day course''' | |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #2, low-dose MTX {{#subobject:9fedf6|Variant=1}}=== | |
− | |||
− | ===Regimen {{#subobject:9fedf6|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 1,523: | Line 1,169: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292437/ Asselin et al. 2011 (POG 9404)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292437/ Asselin et al. 2011 (POG 9404)] | ||
|1996-2001 | |1996-2001 | ||
− | | style="background-color:#1a9851" |Phase 3 ( | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | |[[#Doxorubicin. | + | |[[#Doxorubicin.2C_Mercaptopurine.2C_Methotrexate.2C_Vincristine.2C_Prednisone|Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone]]; high-dose MTX |
− | | style="background-color:# | + | | style="background-color:#fc8d59" |Seems to have inferior EFS |
|- | |- | ||
|} | |} | ||
+ | ''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Doxorubicin (Adriamycin)]] | + | *[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> (maximum dose of 60 mg) IV once per day on days 1, 2, 22 |
− | + | *[[Mercaptopurine (6-MP)]] 50 mg/m<sup>2</sup> (maximum dose of 100 mg) PO once per day on days 22 to 36 | |
− | *[[Mercaptopurine (6-MP)]] | + | *[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> (maximum dose of 80 mg) (route not specified) once on day 2, given 8 to 24 hours after doxorubicin |
− | *[[Methotrexate (MTX)]] | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV push once per week on days 1, 8, 15, 22 |
− | *[[Vincristine (Oncovin)]] | + | ====Glucocorticoid therapy==== |
− | *[[Prednisone (Sterapred)]] | + | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup>/day (maximum dose of 80 mg/day) (route not specified) on days 1 to 22 |
+ | ====Supportive therapy==== | ||
+ | *[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> (maximum dose of 600 mg) IV once per day on days 1, 2, 22, given immediately before each dose of doxorubicin | ||
+ | '''42-day course''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''POG 9404:''' Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011 Jul 28;118(4):874-83. Epub 2011 Apr 7. [ | + | # '''POG 9404:''' Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011 Jul 28;118(4):874-83. Epub 2011 Apr 7. [https://doi.org/10.1182/blood-2010-06-292615 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292437/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21474675/ PubMed] |
==Etoposide & TBI, then allo HSCT {{#subobject:b389e1|Regimen=1}}== | ==Etoposide & TBI, then allo HSCT {{#subobject:b389e1|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:45f841|Variant=1}}=== | ===Regimen {{#subobject:45f841|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
Line 1,555: | Line 1,204: | ||
|} | |} | ||
{{#lst:Allogeneic HSCT|45f841}} | {{#lst:Allogeneic HSCT|45f841}} | ||
− | + | </div></div> | |
− | |||
− | |||
===References=== | ===References=== | ||
− | # '''ALL-BFM 90:''' Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H; German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000 Jun 1;95(11):3310-22. [ | + | # '''ALL-BFM 90:''' Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H; German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000 Jun 1;95(11):3310-22. [https://doi.org/10.1182/blood.V95.11.3310 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/10828010/ PubMed] |
− | ## '''Subgroup analysis:''' Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006 Dec 20;24(36):5742-9. [https://doi.org/10.1200/JCO.2006.06.2679 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17179108 PubMed] | + | ## '''Subgroup analysis:''' Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006 Dec 20;24(36):5742-9. [https://doi.org/10.1200/JCO.2006.06.2679 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17179108/ PubMed] |
− | # '''ALL-BFM 95:''' Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M; German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008 May 1;111(9):4477-89. Epub 2008 Feb 19. Erratum in: Blood. 2009 Apr 30;113(18):4478. Dosage error in article text. [ | + | # '''ALL-BFM 95:''' Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M; German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008 May 1;111(9):4477-89. Epub 2008 Feb 19. Erratum in: Blood. 2009 Apr 30;113(18):4478. Dosage error in article text. [https://doi.org/10.1182/blood-2007-09-112920 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18285545/ PubMed] |
− | ## '''Subgroup analysis:''' Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006 Dec 20;24(36):5742-9. [https://doi.org/10.1200/JCO.2006.06.2679 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17179108 PubMed] | + | ## '''Subgroup analysis:''' Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006 Dec 20;24(36):5742-9. [https://doi.org/10.1200/JCO.2006.06.2679 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17179108/ PubMed] |
− | # '''ALL-SCT-BFM-2003:''' Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1265-74. Epub 2015 Mar 9. [https://doi.org/10.1200/jco.2014.58.9747 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25753432 PubMed] | + | # '''ALL-SCT-BFM-2003:''' Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1265-74. Epub 2015 Mar 9. [https://doi.org/10.1200/jco.2014.58.9747 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25753432/ PubMed] [https://clinicaltrials.gov/study/NCT01423747 NCT01423747] |
− | |||
==L-asparaginase monotherapy {{#subobject:d2a331|Regimen=1}}== | ==L-asparaginase monotherapy {{#subobject:d2a331|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:65da55|Variant=1}}=== | ===Regimen {{#subobject:65da55|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1038/sj.leu.2401310 Amylon et al. 1999 (POG 8704)] |
|1987-1992 | |1987-1992 | ||
| style="background-color:#1a9851" |Phase 3 (E-esc) | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
− | |No L-asp | + | |[[#Observation_888|No L-asp]] |
| style="background-color:#1a9850" |Superior CRR | | style="background-color:#1a9850" |Superior CRR | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Asparaginase (Elspar)]] 25,000 units/m<sup>2</sup> IM once | + | *[[Asparaginase (Elspar)]] 25,000 units/m<sup>2</sup> IM once on day 1 |
− | + | '''7-day cycle for 20 cycles''' | |
− | ''' | + | </div></div> |
− | |||
===References=== | ===References=== | ||
− | # '''POG 8704:''' Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar;13(3):335-42. [https:// | + | # '''POG 8704:''' Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar;13(3):335-42. [https://doi.org/10.1038/sj.leu.2401310 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/10086723/ PubMed] |
− | |||
=Interim maintenance= | =Interim maintenance= | ||
==Mercaptopurine, Methotrexate, Vincristine {{#subobject:ac9042|Regimen=1}}== | ==Mercaptopurine, Methotrexate, Vincristine {{#subobject:ac9042|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
BFM HDMTX: '''<u>B</u>'''erlin '''<u>F</u>'''rankfurt '''<u>M</u>'''uenster '''<u>H</u>'''igh-'''<u>D</u>'''ose '''<u>MTX</u>''' (Methotrexate) regimen | BFM HDMTX: '''<u>B</u>'''erlin '''<u>F</u>'''rankfurt '''<u>M</u>'''uenster '''<u>H</u>'''igh-'''<u>D</u>'''ose '''<u>MTX</u>''' (Methotrexate) regimen | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:25de9f|Variant=1}}=== | ===Regimen {{#subobject:25de9f|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 1,615: | Line 1,254: | ||
|- | |- | ||
|} | |} | ||
− | ''<sup>1</sup>Reported efficacy is based on the 2018 update.''< | + | ''<sup>1</sup>Reported efficacy is based on the 2018 update.'' |
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
====Preceding treatment==== | ====Preceding treatment==== | ||
*[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] induction | *[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] induction | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Mercaptopurine (6-MP)]] | + | *[[Mercaptopurine (6-MP)]] 25 mg/m<sup>2</sup> PO once per day on days 1 to 56 |
*[[Methotrexate (MTX)]] | *[[Methotrexate (MTX)]] | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
− | |||
'''8-week course''' | '''8-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Delayed intensification | *Delayed intensification | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | |||
==Methotrexate, Pegaspargase, Vincristine {{#subobject:dd9475|Regimen=1}}== | ==Methotrexate, Pegaspargase, Vincristine {{#subobject:dd9475|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
COG C-MTX: '''<u>C</u>'''hildren's '''<u>O</u>'''ncology '''<u>G</u>'''roup '''<u>C</u>'''apizzi-style '''<u>MTX</u>''' (Methotrexate) regimen | COG C-MTX: '''<u>C</u>'''hildren's '''<u>O</u>'''ncology '''<u>G</u>'''roup '''<u>C</u>'''apizzi-style '''<u>MTX</u>''' (Methotrexate) regimen | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:1a0b22|Variant=1}}=== | ===Regimen {{#subobject:1a0b22|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 1,654: | Line 1,293: | ||
|} | |} | ||
''Details to be completed; reported efficacy is based on the 2018 update.'' | ''Details to be completed; reported efficacy is based on the 2018 update.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] induction | *[[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine]] versus [[#Cyclophosphamide.2C_Cytarabine.2C_Mercaptopurine.2C_Nelarabine.2C_Pegaspargase.2C_Vincristine|Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine]] induction | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Methotrexate (MTX)]] | *[[Methotrexate (MTX)]] | ||
*[[Pegaspargase (Oncaspar)]] | *[[Pegaspargase (Oncaspar)]] | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
− | |||
'''8-week course''' | '''8-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Delayed intensification | *Delayed intensification | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https:// | + | # '''COG AALL0434:''' Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [https://doi.org/10.1002/pbc.25470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433576/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/25755211/ PubMed] [https://clinicaltrials.gov/study/NCT00408005 NCT00408005] |
− | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [ | + | ## '''Update:''' Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. [https://doi.org/10.1200/JCO.2018.77.7250 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366301/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30138085/ PubMed] |
## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ## '''Update:''' Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. [https://doi.org/10.1200/jco.20.00256 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526719/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32813610/ PubMed] | ||
− | |||
=Relapsed or refractory= | =Relapsed or refractory= | ||
==Mitoxantrone, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone {{#subobject:911679|Regimen=1}}== | ==Mitoxantrone, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone {{#subobject:911679|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:ech1e4|Variant=1}}=== | ===Regimen {{#subobject:ech1e4|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S0140-6736(10)62002-8 Parker et al. 2010 (CCLG ALL R3)] |
− | |2003- | + | |2003-2007 |
− | |style="background-color:#91cf61"|Phase 3, | + | |style="background-color:#91cf61"|Phase 3, fewer than 20 pts in this subgroup (E-switch-ic) |
− | |Idarubicin, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone | + | |[[#Idarubicin.2C_Asparaginase_Erwinia_chrysanthemi.2C_Vincristine.2C_Dexamethasone_888|Idarubicin, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone]] |
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS | |style="background-color:#ffffbf"|Did not meet primary endpoint of PFS | ||
|- | |- | ||
|} | |} | ||
''Note: per the protocol, this regimen is intended only for patients 18 and younger and for patients allergic to pegaspargase. This is the same regimen used in relapsed B-ALL, but this subgroup did not have a statistically significant difference between the regimens.'' | ''Note: per the protocol, this regimen is intended only for patients 18 and younger and for patients allergic to pegaspargase. This is the same regimen used in relapsed B-ALL, but this subgroup did not have a statistically significant difference between the regimens.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 8 | *[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
*[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] 20,000 units IM once per day on days 3, 5, 7, 9, 11, 13, 18, 20, 22, 24, 26, 28 | *[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] 20,000 units IM once per day on days 3, 5, 7, 9, 11, 13, 18, 20, 22, 24, 26, 28 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 3, 10, 17, 24 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 3, 10, 17, 24 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> PO once per day on days 1 to 5, 15 to 19 | *[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> PO once per day on days 1 to 5, 15 to 19 | ||
− | + | ====CNS therapy, prophylaxis==== | |
− | ====CNS prophylaxis==== | + | *[[Methotrexate (MTX)]] by the following age-based criteria: |
− | *[[Methotrexate (MTX)]] | + | **Younger than 2 years old: 8 mg IT once per day on days 1 & 8 |
− | ** | ||
**Age 2: 10 mg IT once per day on days 1 & 8 | **Age 2: 10 mg IT once per day on days 1 & 8 | ||
− | ** | + | **Older than 2 years old: 12 mg IT once per day on days 1 & 8 |
− | |||
'''4-week course''' | '''4-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*See paper for details of treatment beyond induction | *See paper for details of treatment beyond induction | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''CCLG ALL R3:''' Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. Epub 2010 Dec 3. [https:// | + | # '''CCLG ALL R3:''' Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. Epub 2010 Dec 3. [https://doi.org/10.1016/S0140-6736(10)62002-8 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21131038/ PubMed] [https://clinicaltrials.gov/study/NCT00967057 NCT00967057] |
==Mitoxantrone, Pegaspargase, Vincristine, Dexamethasone {{#subobject:910a79|Regimen=1}}== | ==Mitoxantrone, Pegaspargase, Vincristine, Dexamethasone {{#subobject:910a79|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:e3cbe4|Variant=1}}=== | ===Regimen {{#subobject:e3cbe4|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S0140-6736(10)62002-8 Parker et al. 2010 (CCLG ALL R3)] |
− | |2003- | + | |2003-2007 |
− | |style="background-color:#91cf61"|Phase 3, | + | |style="background-color:#91cf61"|Phase 3, fewer than 20 pts in this subgroup (E-switch-ic) |
− | |Idarubicin, Pegaspargase, Vincristine, Dexamethasone | + | |[[#Idarubicin.2C_Pegaspargase.2C_Vincristine.2C_Dexamethasone_888|Idarubicin, Pegaspargase, Vincristine, Dexamethasone]] |
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS | |style="background-color:#ffffbf"|Did not meet primary endpoint of PFS | ||
|- | |- | ||
|} | |} | ||
''Note: per the protocol, this regimen is intended only for patients 18 and younger. This is the same regimen used in relapsed B-ALL, but this subgroup did not have a statistically significant difference between the regimens.'' | ''Note: per the protocol, this regimen is intended only for patients 18 and younger. This is the same regimen used in relapsed B-ALL, but this subgroup did not have a statistically significant difference between the regimens.'' | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 8 | *[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
*[[Pegaspargase (Oncaspar)]] 1000 units/m<sup>2</sup> IM once per day on days 3 & 18 | *[[Pegaspargase (Oncaspar)]] 1000 units/m<sup>2</sup> IM once per day on days 3 & 18 | ||
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 3, 10, 17, 24 | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 3, 10, 17, 24 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> PO once per day on days 1 to 5, 15 to 19 | *[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> PO once per day on days 1 to 5, 15 to 19 | ||
− | + | ====CNS therapy, prophylaxis==== | |
− | ====CNS prophylaxis==== | + | *[[Methotrexate (MTX)]] by the following age-based criteria: |
− | *[[Methotrexate (MTX)]] | + | **Younger than 2 years old: 8 mg IT once per day on days 1 & 8 |
− | ** | ||
**Age 2: 10 mg IT once per day on days 1 & 8 | **Age 2: 10 mg IT once per day on days 1 & 8 | ||
− | ** | + | **Older than 2 years old: 12 mg IT once per day on days 1 & 8 |
− | |||
'''4-week course''' | '''4-week course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*See paper for details of treatment beyond induction | *See paper for details of treatment beyond induction | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''CCLG ALL R3:''' Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. Epub 2010 Dec 3. [https:// | + | # '''CCLG ALL R3:''' Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. Epub 2010 Dec 3. [https://doi.org/10.1016/S0140-6736(10)62002-8 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21131038/ PubMed] [https://clinicaltrials.gov/study/NCT00967057 NCT00967057] |
− | |||
==Nelarabine monotherapy {{#subobject:bb7a38|Regimen=1}}== | ==Nelarabine monotherapy {{#subobject:bb7a38|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:44a025|Variant=1}}=== | ===Regimen {{#subobject:44a025|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
− | !style="width: 25%"| | + | !style="width: 25%"|Dates of enrollment |
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
Line 1,764: | Line 1,401: | ||
|[https://doi.org/10.1200/JCO.2005.03.426 Berg et al. 2005] | |[https://doi.org/10.1200/JCO.2005.03.426 Berg et al. 2005] | ||
|1997-2002 | |1997-2002 | ||
− | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 (RT) |
|ORR: 14-55% | |ORR: 14-55% | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1111/bjh.14874 Zwaan et al. 2017 (GSK 111081)] |
|2009-2014 | |2009-2014 | ||
|style="background-color:#91cf61"|Phase 4 | |style="background-color:#91cf61"|Phase 4 | ||
Line 1,773: | Line 1,410: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 5 | *[[Nelarabine (Arranon)]] 650 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 5 | ||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20;23(15):3376-82. [https://doi.org/10.1200/JCO.2005.03.426 link to original article] ''' | + | # Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20;23(15):3376-82. [https://doi.org/10.1200/JCO.2005.03.426 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15908649/ PubMed] |
− | # '''GSK 111081:''' Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, Ranganathan S, Leverger G. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017 Oct;179(2):284-293. Epub 2017 Aug 2. [https:// | + | # '''GSK 111081:''' Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, Ranganathan S, Leverger G. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017 Oct;179(2):284-293. Epub 2017 Aug 2. [https://doi.org/10.1111/bjh.14874 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28771663/ PubMed] [https://clinicaltrials.gov/study/NCT00866671 NCT00866671] |
− | |||
[[Category:T-cell acute lymphoblastic leukemia regimens]] | [[Category:T-cell acute lymphoblastic leukemia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] |
Latest revision as of 17:12, 17 July 2024
Section editor | |
---|---|
David Noyd, MD, MPH University of Washington Seattle, WA, USA |
This page contains studies that were specific to pediatric populations. For the more general T-cell acute lymphoblastic leukemia page, follow this link.
16 regimens on this page
17 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Pediatric Acute Lymphoblastic Leukemia.
Upfront therapy
COG AALL0434 protocol
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Winter et al. 2015 (COG AALL0434) | 2007-2014 | Phase 3 (E-RT-esc) | Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine | Seems to have superior DFS1 (primary endpoint) | Similar toxicity |
1Reported efficacy is based on the 2020 update.
Induction, Arms B (Nelarabine Arms)
All Patients
Chemotherapy
- Pegaspargase (Oncaspar) 2,500 units/m2 IV once on day 4 (OR 5 OR 6)
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22
- Daunorubicin (Cerubidine) 25 mg/m2 IV over 1 to 15 minutes once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisone (Sterapred) 30 mg/m2 PO twice per day on days 1 to 28 (Total of 60 mg/m2/day, DO NOT TAPER)
CNS therapy, prophylaxis
- Cytarabine (Ara-C) IT once at time of diagnostic lumbar puncture or Day 1
Age in years, rounded to the nearest hundredth | Initial Dose |
---|---|
1.00 to 1.99 | 30 mg |
2.00 to 2.99 | 50 mg |
3.00 or older | 70 mg |
- Methotrexate (MTX) IT once per day on days 8, 29 (CNS3 patients on days 15, 22 ALSO)
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
29-day course
Consolidation, Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine
Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.
Preceding treatment
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once per day over 30 minutes on days 8, 50
- Must reduce urine specific gravity to less than or equal to 1.015 prior to administration
- Cytarabine (Ara-C) 75 mg/m2 IV over 1 to 30 minutes or SC once per day on days 8 to 11, 15 to 18, 50 to 53, 57 to 60
- Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 8 to 21, 50 to 63
- DO NOT escalate or modify dose based on blood counts during this course.
- Nelarabine (Arranon) 650 mg/m2 IV once per day over 60 minutes on days 1 to 5, 43 to 47
- Pegaspargase (Oncaspar) 2,500 units/m2 IM or IV over 1 to 2 hours once per day on days 22 & 64
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 22, 29, 64, 71
CNS therapy, prophylaxis
- Methotrexate (MTX) IT on days 15, 22, 57, 64 (Omit Day 22 if CNS3 T-ALL)
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
- Whole-brain irradiation by the following risk-based criteria:
- CNS3 T-ALL: 1,800cGy in 10 once daily fractions.
- Intermediate/High Risk ARM B: 1,200 cGy in 8 once-daily fractions given during weeks 4 and 5 of consolidation
71-day course
Subsequent treatment
- Interim maintenance
Interim Maintenance, with Capizzi MTX (Arms A and B)
Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.
Preceding treatment
Chemotherapy
- Methotrexate (MTX) 100 mg/m2 IV once on day 1, then 150 mg/m2 IV once on day 11, then 200 mg/m2 IV once on day 21, then 250 mg/m2 IV once on day 31, then 300 mg/m2 IV once on day 41
- If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose.
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41
- Pegaspargase (Oncaspar) 2,500 units/m2 IM or IV over 1 to 2 hours once per day on days 2, 22
CNS therapy, prophylaxis
- Methotrexate (MTX) IT once on days 1, 31
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Delayed Intensification, Nelarabine Arms (Arms B and D)
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (max dose 2 mg) on days 1, 8, 15, 43, 50
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV over 30 minutes once on day 29
- Cytarabine (Ara-C) 75 mg/m2 SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39
- Doxorubicin (Adriamycin) 25 mg/m2 IV push/infusion over 1 to 15 minutes once per day on days 1, 8, 15
- Pegaspargase (Oncaspar) 2,500 units/m2 IM or IV over 1 to 2 hours on day 4 (OR 5 OR 6), 43
- Thioguanine (Tabloid) 60 mg/m2 PO once per day on days 29 to 42
- Should not be given to patients receiving CRT (Arm D and CNS3 T-ALL patients)
- Nelarabine (Arranon) 650 mg/m2 IV 60 minutes once per day on days 29 to 33
Glucocorticoid therapy
- Dexamethasone (Decadron) 5 mg/m2 IV or PO twice per day on days 1 to 7, 15 to 21 (10 mg/m2/day, divided twice per day).
CNS therapy, prophylaxis
- Methotrexate (MTX) IT once on days 1, 29, 36
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
Radiotherapy
- Total body irradiation (TBI) by the following risk-based criteria:
- Arm D Only: 1,200 cGy in 8 once daily fractions to start on day 50 of DI
- CNS3 T-ALL: 1,800 cGy in 10 once daily fractions to start on day 50 of DI
63-day course
Maintenance, Arms B and D
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) on days 1, 57
- Mercaptopurine (6-MP) 75 mg/m2 PO once per day on days 1 to 28, 36 to 84
- Methotrexate (MTX) 20 mg/m2 PO on days 8, 15, 22, 36, 43, 50, 57, 64, 71, 78
- No dose escalation recommended for the first maintenance cycle
- Thereafter, for ANC at least 1500 μL on 3 CBCs done over 6 weeks or 2 monthly CBCs, increase dose of methotrexate or mercaptopurine by 25%
- Nelarabine (Arranon) 650 mg/m2 IV over 60 minutes once per day on days 29 to 33
- DO NOT Administer with other Chemotherapy agents
Glucocorticoid therapy
- Prednisone (Sterapred) 20 mg/m2 PO twice per day on days 1 to 5 and 57 to 61 (Total of 40 mg/m2/day, divided twice per day)
CNS prophylaxis
- Methotrexate (MTX) IT once on day 1
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
Repeat above cycle for a total of 3 cycles.
3 cycles
Maintenance, continuation after cycle 3 (Arms B and D)
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 29, 57
- Mercaptopurine (6-MP) 75 mg/m2 PO once per day on days 1 to 84
- Methotrexate (MTX) 20 mg/m2 PO once per day on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78
- No dose escalation recommended for the first maintenance cycle
- Thereafter, for ANC at least 1500 μL on 3 CBCs done over 6 weeks or 2 monthly CBCs, increase dose of methotrexate or mercaptopurine by 25%
Glucocorticoid therapy
- Prednisone (Sterapred) 20 mg/m2 PO twice per day on days 1 to 5, 29 to 33, 57 to 61 (Total of 40 mg/m2/day, divided twice per day)
CNS prophylaxis
- Methotrexate (MTX) IT once on day 1
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
Duration
- Girls T-ALL: Continue repeating 12 week cycles of maintenance therapy II until the total duration of therapy is two years from the start of Interim Maintenance (~ Week 121)
- Boys T-ALL: Continue to repeat 12 week cycles of Maintenance therapy II until the total duration of therapy is three years from the start of Interim Maintenance (~ Week 173).
- T-NHL patients (regardless of gender): Continue to repeat 12 week cycles of maintenance therapy II until the total duration reaches two years from the start of Interim Maintenance (~ Week 121)
84-day course
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
COG AALL1231 Protocol Arm A
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Teachey et al. 2022 (COG AALL1231) | 2014-2017 | Phase 3 (C) | COG AALL1231 Protocol Arm B (with bortezomib) | Did not meet primary endpoint of EFS |
Note: Per the protocol, it is intended only for patients greater than 1 and less than 31 years of age.
Induction
All T-ALL and T-LLy patients
Chemotherapy
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours once on day 4, 18
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22
- Daunorubicin (Cerubidine) 25 mg/m2 IV over 1 to 15 minutes once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) 3 mg/m2 IV or PO twice per day on days 1 to 28 (DO NOT TAPER)
CNS prophylaxis
- Cytarabine (Ara-C) IT once on day 1 or at the time of diagnostic lumbar puncture (if within 72 hours of protocol initiation)
Age in years, rounded to the nearest hundredth | Initial Dose |
---|---|
1.00 to 1.99 | 30 mg |
2.00 to 2.99 | 50 mg |
3.00 or older | 70 mg |
- Methotrexate (MTX) IT once per day on days 8, 29
CNS treatment
- CNS3 patients also receive Methotrexate (MTX) IT on days 15, 22
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
Consolidation
All T-ALL and T-LLy Patients
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once per day over 30 to 60 minutes on days 1, 29
- Cytarabine (Ara-C) 75 mg/m2 IV over 1 to 30 minutes or SC once per day on days 1 to 4, 8 to 11, 29 to 32, 36 to 39
- Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 1 to 14, 29 to 42
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours once per day on days 15, 43
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days on days 15, 22, 43, 50
CNS prophylaxis
- Methotrexate (MTX) IT once per day on days 1, 8, 15, 22
- CNS3 patients and CNS3 T-LLy: Omit days 15, 22
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Interim Maintenance, SR patients, with CMTX
SR Patients Receive After Consolidation
Chemotherapy
- Methotrexate (MTX) 100 mg/m2 IV once on day 1, then 150 mg/m2 IV once on day 11, then 200 mg/m2 IV once on day 21, then 250 mg/m2 IV once on day 31, then 300 mg/m2 IV once on day 41
- If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours once per day on days 2, 22
CNS prophylaxis
- Methotrexate (MTX) IT once per day on days 1 & 31
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Delayed Intensification
All T-ALL and T-LLy Patients
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) on days 1, 8, 15, 43, 50
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV over 30 minutes once on day 29
- Cytarabine (Ara-C) 75 mg/m2 SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39
- Doxorubicin (Adriamycin) 25 mg/m2 IV push or infusion over 1 to 15 minutes once per day on days 1, 8, 15
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours on day 4, 18, 43
- Thioguanine (Tabloid) 60 mg/m2 PO once per day on days 29 to 42
Glucocorticoid therapy
- Dexamethasone (Decadron) 5 mg/m2 IV or PO twice per day on days 1 to 7, 15 to 21 (10 mg/m2/day, divided twice per day)
CNS prophylaxis
- Methotrexate (MTX) IT once per day on days 1, 29, 36
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Delayed Intensification, IR patients
All T-ALL and T-LLy Patients
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (max dose 2 mg) on days 1, 8, 15, 43, 50
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV over 30 minutes once on day 29
- Cytarabine (Ara-C) 75 mg/m2 SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39
- Doxorubicin (Adriamycin) 25 mg/m2 IV push or infusion over 1 to 15 minutes once per day on days 1, 8, 15
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours on day 4, 18, 43
- Thioguanine (Tabloid) 60 mg/m2 PO once per day on days 29 to 42
Glucocorticoid therapy
- Dexamethasone (Decadron) 5 mg/m2 IV or PO twice per day on days 1 to 7, 15 to 21 (10 mg/m2/day, divided twice per day)
CNS prophylaxis
- Methotrexate (MTX) IT once per day on days 1, 29, 36
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Interim Maintenance, #1 with HDMTX - ALL IR Patients
SR and VHR T-ALL and T-LLy DO NOT RECEIVE
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 15, 29, 43
- Mercaptopurine (6-MP) 25 mg/m2 PO once per day on days 1 to 56.
- High Dose Methotrexate (MTX) 5,000 mg/m2 IV over 24 hours on days 1, 15, 29, 43.
- Methotrexate (MTX) 500 mg/m2 IV infused over 30 minutes, then 4500 mg/m2 given by continuous IV infusion over 23.5 hours
Supportive therapy
- Leucovorin (Folinic acid) 15 mg/m2 x a minimum of 3 doses PO or IV (given at 42, 48, and 54 hours after the START of high dose methotrexate infusion) on days 3, 4, 17, 18, 31, 32, 45, 46
CNS prophylaxis
- Methotrexate (MTX) IT once per day on days 1, 29, 36
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Interim Maintenance, #2 with CMTX - ALL IR Patients
IR T-ALL and T-LLy Patients receive this after DI as IM#2
Chemotherapy
- Methotrexate (MTX) 100 mg/m2 IV once on day 1, then 150 mg/m2 IV once on day 11, then 200 mg/m2 IV once on day 21, then 250 mg/m2 IV once on day 31, then 300 mg/m2 IV once on day 41
- If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours once per day on days 2, 22
CNS prophylaxis
- Methotrexate (MTX) IT once per day on days 1 & 31
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Intensification, Block 1 (VHR patients)
VHR Patients receive immediately after consolidation
Chemotherapy
- High Dose Methotrexate (MTX) 5000 mg/m2 IV over 24 hours on day 1 ONLY.
- Methotrexate (MTX) 500 mg/m2 IV infused over 30 minutes, then 4500 mg/m2 given by continuous IV infusion over 23.5 hours
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) on days 1, 6
- Cyclophosphamide (Cytoxan) 200 mg/m2 every 12 hours IV over 1 to 6 hours x 5 doses on days 2 to 4
- High Dose Cytarabine (Ara-C) 2000 mg/m2 every 12 hours IV over 3 hours x 2 doses on day 5
- Pegaspargase (Oncaspar) 2500 units/m2 IV over 1 to 2 hours on day 6
- Administer 3 hours after completion of the second high dose Cytarabine (Ara-C) infusion
Glucocorticoid therapy
- Dexamethasone (Decadron) 10 mg/m2 IV or PO twice per day on days 1 to 5 (20 mg/m2/day, divided twice per day)
Supportive therapy
- Leucovorin (Folinic acid) 15 mg/m2 x a minimum of 3 doses PO or IV (given at 42, 48, and 54 hours after the START of high dose methotrexate infusion) on days 3, 4
- Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day beginning on day 7 and until WBC count more than 3 x 109/L
- Alternative: Pegfilgrastim (Neulasta) 100 mcg/kg (Maximum dose of 6 mg) SC once during the 7 to 11th day
CNS prophylaxis, Triple Intrathecal Therapy
- Methotrexate (MTX) by the following age-based criteria:
- 1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- Hydrocortisone (Cortef) by the following age-based criteria:
- 1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- Cytarabine (Ara-C) by the following age-based criteria:
- 1 up to 2 years old: 16 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 20 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 24 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 30 mg IT on day 1, given 2 hours after the start of HD MTX infusion
Intensification, Block 2
Chemotherapy
- High Dose Methotrexate (MTX) 5000 mg/m2 IV over 24 hours on day 1 ONLY
- Methotrexate (MTX) 500 mg/m2 IV infused over 30 minutes, then 4500 mg/m2 given by continuous IV infusion over 23.5 hours
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) on days 1, 6
- Ifosfamide (Ifex) 800 mg/m2 every 12 hours IV infusion over 1 hour x 5 doses on days 2 to 4
- Start Immediately after completion of high dose Methotrexate (MTX) infusion.
- Daunorubicin (Cerubidine) 30 mg/m2 IV over 1 to 15 minutes on day 5
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours on day 6
Glucocorticoid therapy
- Dexamethasone (Decadron) 10 mg/m2 IV or PO twice per day on days 1 to 5 (20 mg/m2/day, divided twice per day)
Supportive therapy
- Leucovorin (Folinic acid) 15 mg/m2 x a minimum of 3 doses PO or IV (given at 42, 48, and 54 hours after the START of high dose methotrexate infusion) on days 3, 4
- Mesna (Mesnex) 300 mg/m2 at hour 0, 4, and 8 from the start of each ifosfamide infusion on days 2 to 4
- Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day beginning on day 7 and until WBC count more than 3 x 109/L
- Alternative: Pegfilgrastim (Neulasta) 100 mcg/kg (Max 6 mg/dose) SC once during the 7 to 11th day
CNS prophylaxis, Triple Intrathecal Therapy
- Methotrexate (MTX) by the following age-based criteria:
- 1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- Hydrocortisone (Cortef) by the following age-based criteria:
- 1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- Cytarabine (Ara-C) by the following age-based criteria:
- 1 up to 2 years old: 16 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 20 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 24 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 30 mg IT on day 1, given 2 hours after the start of HD MTX infusion
Intensification, Block 3
Chemotherapy
- High Dose Cytarabine (Ara-C) 2,000 mg/m2 every 12 hours IV over 3 hours x 4 doses on days 1, 2
- Etoposide (Vepesid) 100 mg/m2 every 12 hours IV over 1 to 2 hours x 5 doses on days 3 to 5
- First dose to be given 12 hours after the start of the 4th high dose Cytarabine (Ara-C) on day 2
- Infusion rate should not exceed 300 mg/m2/hour (10 mg/kg/hour)
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours on day 6
Glucocorticoid therapy
- Dexamethasone (Decadron) 10 mg/m2 IV or PO twice per day on days 1 to 5 (20 mg/m2/day, divided twice per day)
Supportive therapy
- Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day beginning on day 7 and until WBC count more than 3 x 109/L
- Alternative: Pegfilgrastim (Neulasta) 100 mcg/kg (Max 6 mg/dose) SC once during the 7 to 11th day
CNS therapy, Triple Intrathecal Therapy
- Methotrexate (MTX) by the following age-based criteria:
- 1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- Hydrocortisone (Cortef) by the following age-based criteria:
- 1 up to 2 years old: 8 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 10 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 12 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 15 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- Cytarabine (Ara-C) by the following age-based criteria:
- 1 up to 2 years old: 16 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 2 up to 3 years old: 20 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 3 up to 9 years old: 24 mg IT on day 1, given 2 hours after the start of HD MTX infusion
- 9 years old and older: 30 mg IT on day 1, given 2 hours after the start of HD MTX infusion
Delayed Intensification
All T-ALL and T-LLy Patients
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) on days 1, 8, 15, 43, 50
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV over 30 minutes once on day 29
- Cytarabine (Ara-C) 75 mg/m2 SC or IV over 1 to 30 minutes on days 29 to 32, 36 to 39
- Doxorubicin (Adriamycin) 25 mg/m2 IV push or infusion over 1 to 15 minutes once per day on days 1, 8, 15
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours on day 4, 18, 43
- Thioguanine (Tabloid) 60 mg/m2 PO once per day on days 29 to 42
Glucocorticoid therapy
- Dexamethasone (Decadron) 5 mg/m2 IV or PO twice per day on days 1 to 7 and 15 to 21 (10 mg/m2/day, divided twice per day)
CNS therapy, prophylaxis
- Methotrexate (MTX) IT once on days 1, 29, 36
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Interim Maintenance, with CMTX
VHR Patients receive after DI
Chemotherapy
- Methotrexate (MTX) 100 mg/m2 IV once on day 1, then 150 mg/m2 IV once on day 11, then 200 mg/m2 IV once on day 21, then 250 mg/m2 IV once on day 31, then 300 mg/m2 IV once on day 41
- If delay is necessary for myelosuppression and/or Grade 3 mucositis, discontinue escalation and resume at 80% of last dose
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 11, 21, 31, 41
- Pegaspargase (Oncaspar) 2,500 units/m2 IV over 1 to 2 hours once per day on days 2, 22
CNS therapy, prophylaxis
- Methotrexate (MTX) IT once on days 1, 31
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
56-day course
Maintenance, all patients
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 29, 57
- Mercaptopurine (6-MP) 75 mg/m2 PO once per day on days 1 to 84
- Methotrexate (MTX) 20 mg/m2 once per day on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78
- Omit day 29 of the first FOUR cycles for SR T-ALL and T-LLy patients
- Omit day 29 of the first TWO cycles for IR T-ALL and T-LLy patients
Glucocorticoid therapy
- Dexamethasone (Decadron) 3 mg/m2 IV or PO twice per day on days 1 to 5, 29 to 33, 57 to 61 (6 mg/m2/day, divided twice per day)
CNS therapy, prophylaxis
- Methotrexate (MTX) IT once on days 1
- Also on day 29 of the first FOUR cycles for SR patients
- Also on day 29 of the first TWO cycles for IR patients
Age in years, rounded to the nearest hundredth | Dose |
---|---|
1.00 to 1.99 | 8 mg |
2.00 to 2.99 | 10 mg |
3.00 to 8.99 | 12 mg |
9.00 or older | 15 mg |
Radiotherapy
- Total body irradiation (TBI) during the first cycle of maintenance, by the following histology- and risk-based criteria:
- T-ALL AND CNS1 VHR: 1200 cGy
- T-ALL AND CNS2 VHR: 1200 cGy
- T-ALL AND CNS3 IR: 1800 cGy
- T-ALL AND CNS3 VHR: 1800 cGy
- T-LLy AND CNS3 IR: 1800 cGy
- T-LLy AND CNS3 VHR: 1800 cGy
Duration of therapy:
- SR and IR T-ALL Girls: repeat 12 week cycles of maintenance for a total duration of 2 years from Interim Maintenance start.
- VHR T-ALL Girls: Repeat 12 week cycles of maintenance for a total duration of 2 years from Intensification Block 1 start.
- SR and IR T-ALL Boys: repeat 12 week cycles of maintenance for a total duration of 3 years from Interim Maintenance start.
- VHR T-ALL Boys: Repeat 12 week cycles of maintenance for a total duration of 3 years from Intensification Block 1 start.
- T-LLy regardless of gender: repeat 12 week cycles of maintenance for a total duration of 2 years from Interim Maintenance start.
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
- COG AALL1231: Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. Epub 2022 Mar 10. link to original article link to PMC article PubMed NCT02112916
Pre-phase
Methylprednisolone monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Place et al. 2015 (DFCI 05-001) | 2005-2011 | Non-randomized part of phase 3 RCT |
Burns et al. 2020 (DFCI 11-001) | 2012-2015 | Non-randomized part of phase 3 RCT |
Note: Burns et al. 2020 is both an update of DFCI 05-001 and the primary publication of DFCI 11-001.
Glucocorticoid therapy
- Methylprednisolone (Solumedrol) 8 mg/m2 IV three times per day on days 1 to 3
3-day course
Subsequent treatment
- DFCI 05-001: Doxorubicin, L-asparaginase, Methotrexate, Vincristine, Methylprednisolone versus Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone induction
- DFCI 11-001: Calaspargase, Doxorubicin, Methotrexate, Vincristine, Methylprednisolone versus Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone induction
References
- DFCI 05-001: Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. Epub 2015 Nov 6. link to original article PubMed NCT00400946
- Pooled update: Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. link to original article dosing details in supplement have been reviewed by our editors link to PMC article PubMed
- DFCI 11-001: Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. link to original article dosing details in supplement have been reviewed by our editors link to PMC article PubMed NCT01574274
- Update: Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. Epub 2021 Jul 6. link to original article PubMed
Upfront induction therapy
Daunorubicin, L-Asparaginase, Vincristine, Dexamethasone
Regimen, modified ABFM
Study | Dates of enrollment | Evidence |
---|---|---|
Sato et al. 2023 (ALL-T11) | 2011-12-01 to 2017-11-30 | Phase 2 |
Note: Day counts included a 7-day pre-phase, not shown here.
Chemotherapy
- Daunorubicin (Cerubidine) 30 mg/m2 IV once per day on days 8, 15, 22, 29
- Asparaginase (Elspar) 5000 units/m2 IM or IV once per day on days 12, 15, 18, 21, 24, 27, 30, 33
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 8, 15, 22, 29
Glucocorticoid therapy
- Dexamethasone (Decadron) by the following age-based criteria:
- Younger than 10 years old: 10 mg/m2/day PO on days 8 to 28
- 10 years old or older: 10 mg/m2/day PO on days 8 to 14, 22 to 28
CNS therapy, prophylaxis
- Cytarabine (Ara-C) by the following age-based criteria:
- Younger than 1 year old: 16 mg IT once per day on days 12 & 33
- 1 to 1.99 years old: 20 mg IT once per day on days 12 & 33
- 2 to 2.99 years old: 26 mg IT once per day on days 12 & 33
- 3 years old or older: 30 mg IT once per day on days 12 & 33
- Methotrexate (MTX) by the following age-based criteria:
- Younger than 1 year old: 6 mg IT once per day on days 12 & 33
- 1 to 1.99 years old: 8 mg IT once per day on days 12 & 33
- 2 to 2.99 years old: 10 mg IT once per day on days 12 & 33
- 3 years old or older: 12 mg IT once per day on days 12 & 33
- [[Prednisolone (Millipred) by the following age-based criteria
- Younger than 1 year old: 4 mg IT once per day on days 12 & 33
- 1 to 1.99 years old: 6 mg IT once per day on days 12 & 33
- 2 to 2.99 years old: 8 mg IT once per day on days 12 & 33
- 3 years old or older: 10 mg IT once per day on days 12 & 33
4-week course
Subsequent treatment
- See paper for details
References
- ALL-T11: Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Lancet Haematol. 2023 Jun;10(6):e419-e432. Epub 2023 May 8. Erratum in: Lancet Haematol. 2023 Jun;10(6):e399. link to original article dosing details in supplement have been reviewed by our editors PubMed jRCTs041180145
Daunorubicin, Pegaspargase, Vincristine, Dexamethasone
Regimen, modified ABFM
Study | Dates of enrollment | Evidence |
---|---|---|
Vora et al. 2013 (UKALL 2003) | 2003-2011 | Non-randomized part of phase 2 RCT |
Chemotherapy
- Daunorubicin (Cerubidine) 25 mg/m2 IV over 1 to 15 minutes once per day on days 1, 8, 15, 22
- Pegaspargase (Oncaspar) 2500 units/m2 IV over 1 to 2 hours once per day on days 4 & 18
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Dexamethasone (Decadron) 3 mg/m2 IV or PO twice per day on days 1 to 28
CNS therapy, prophylaxis
- Cytarabine (Ara-C) by the following age-based criteria:
- 1 to 1.99 years old: 30 mg IT once on day 1
- 2 to 2.99 years old: 50 mg IT once on day 1
- 3 years old or older: 70 mg IT once on day 1
- Methotrexate (MTX) by the following age-based criteria:
- 1 to 1.99 years old: 8 mg IT once per day on days 8 & 29
- 2 to 2.99 years old: 10 mg IT once per day on days 8 & 29
- 3 to 8.99 years old: 12 mg IT once per day on days 8 & 29
- 9 years old or older: 15 mg IT once per day on days 8 & 29
4-week course
Subsequent treatment
References
- UKALL 2003: Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. Epub 2013 Feb 7. link to original article PubMed ISRCTN07355119
Daunorubicin, Pegaspargase, Vincristine, Prednisone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Winter et al. 2015 (COG AALL0434) | 2007-2014 | Non-randomized part of phase 3 RCT |
Chemotherapy
- Daunorubicin (Cerubidine) 25 mg/m2 IV once per day on days 1, 8, 15, 22
- Pegaspargase (Oncaspar) 2500 units/m2 IV once on day 5 +/- 1 day
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisone (Sterapred) 30 mg/m2 PO twice per day on days 1 to 28
4-week course
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
DOLP
DOLP: Daunorubicin, Oncovin (Vincristine), L-Asparaginase, Prednisone
DVPA: Daunorubicin, Vincristine, Prednisone, Asparaginase
Regimen, BFM 76/79 Phase I
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Gaynon et al. 1988 (CCG-106) | 1983-05 to 1984-11 | Phase 3 (E-esc) | 1. Control regimen | Seems to have superior EFS36 |
2. New York regimen | Did not meet primary endpoint of EFS36 | |||
Steinherz et al. 1998 (CCG-123) | 1983-1985 | Phase 3 (C) | 1. LSA2-L2 & WBRT 2. LSA-L2 3. New York regimen |
Did not meet primary endpoint of EFS |
Note: the specific days of L-asparaginase are not specified; the schedule here is similar to those of other similar protocols.
Chemotherapy
- Daunorubicin (Cerubidine) 25 mg/m2 IV once per day on days 1, 8, 15, 22
- Asparaginase (Elspar) 6000 units/m2 IM once per day on days 3, 5, 7, 10, 12, 14, 17, 19, 21
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisone (Sterapred) 60 mg/m2/day PO on days 1 to 28, then tapered over 2 weeks
CNS therapy
- Methotrexate (MTX) IT once per day on days 1, 15, 29 (dose not specified)
6-week course
Subsequent treatment
- BFM 76/79 Phase II
References
- CCG-106: Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, Sather HN, Hammond GD. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet. 1988 Oct 22;2(8617):921-4. link to original article PubMed
- CCG-123: Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, Bleyer WA. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer. 1998 Feb 1;82(3):600-12. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Place et al. 2015 (DFCI 05-001) | 2005-2011 | Phase 3 (E-switch-ic) | Doxorubicin, L-asparaginase, Methotrexate, Vincristine, Methylprednisolone | Did not meet secondary endpoint of DFS | Less anxiety |
Burns et al. 2020 (DFCI 11-001) | 2012-2015 | Phase 3 (C) | Calaspargase, Doxorubicin, Methotrexate, Vincristine, Methylprednisolone | Not reported |
Note: Burns et al. 2020 is both an update of DFCI 05-001 and the primary publication of DFCI 11-001. Day numbering takes into account the pre-phase.
Preceding treatment
- Methylprednisolone pre-phase
Chemotherapy
- Doxorubicin (Adriamycin) 30 mg/m2 IV once per day on days 4 & 5
- Methotrexate (MTX) 40 mg/m2 IV once on day 6
- Pegaspargase (Oncaspar) 2500 units/m2 IV once on day 7
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 4, 11, 18, 25
Glucocorticoid therapy
- Methylprednisolone (Solumedrol) 8 mg/m2 IV three times per day on days 4 to 32
Supportive therapy
- Dexrazoxane (Zinecard) 300 mg/m2 IV once per day on days 4 & 5
28-day course
CNS therapy, prophylaxis
- Cytarabine (Ara-C) IT once per day on days 1 & 18
- Day 18 dose is admixed with MTX and HC
- Methotrexate (MTX) IT once per day on days 18 & 32
- Day 18 dose is admixed with Ara-C and HC
- Hydrocortisone (Cortef) IT once on day 18, admixed with Ara-C and MTX
Subsequent treatment
- Doxorubicin, Mercaptopurine, Methotrexate, Vincristine consolidation (IA)
References
- DFCI 05-001: Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. Epub 2015 Nov 6. link to original article PubMed NCT00400946
- Pooled update: Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. link to original article dosing details in supplement have been reviewed by our editors link to PMC article PubMed
- DFCI 11-001: Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. link to original article dosing details in supplement have been reviewed by our editors link to PMC article PubMed NCT01574274
- Update: Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. Epub 2021 Jul 6. link to original article PubMed
Consolidation after upfront therapy
Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Winter et al. 2015 (COG AALL0434) | 2007-2014 | Phase 3 (E-RT-esc) | Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine | Seems to have superior DFS1 (primary endpoint) | Similar toxicity |
1Reported efficacy is based on the 2020 update.
Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.
Preceding treatment
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once per day on days 8 & 50
- Cytarabine (Ara-C) 75 mg/m2 IV or SC once per day on days 8 to 11, 15 to 18, 50 to 53, 57 to 60
- Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 8 to 21, 50 to 63
- Nelarabine (Arranon) 650 mg/m2 IV once per day on days 1 to 5, 43 to 47
- Pegaspargase (Oncaspar) 2500 units/m2 IM once per day on days 22 & 64
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 22, 64, 71
CNS therapy, prophylaxis
- Methotrexate (MTX) (dose not specified) IT on days 15, 22, 57, 64
- Whole-brain irradiation in some arms (see paper for details)
71-day course
Subsequent treatment
- Interim maintenance; see paper for details
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine
Regimen variant #1
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Winter et al. 2015 (COG AALL0434) | 2007-2014 | Phase 3 (C) | Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine | Not reported | Similar toxicity |
Note: although the induction doses of vincristine are capped at 2 mg, capping is not mentioned in the subsequent phases of treatment.
Preceding treatment
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once per day on days 8 & 50
- Cytarabine (Ara-C) 75 mg/m2 IV or SC once per day on days 8 to 11, 15 to 18, 50 to 53, 57 to 60
- Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 8 to 21, 50 to 63
- Pegaspargase (Oncaspar) 2500 units/m2 IM once per day on days 22 & 64
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 22, 64, 71
CNS therapy, prophylaxis
- Methotrexate (MTX) (dose not specified) IT on days 15, 22, 57, 64
- Whole-brain irradiation in some arms (see paper for details)
71-day course
Subsequent treatment
- Interim maintenance; see paper for details
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Teachey et al. 2022 (COG AALL1231) | 2014-2017 | Non-randomized part of phase 3 RCT |
Note: Per the protocol, it is intended only for patients greater than 1 and less than 31 years of age.
Preceding treatment
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV over 30 to 60 minutes once per day on days 1 & 29
- Cytarabine (Ara-C) 75 mg/m2 IV or SC once per day on days 1 to 4, 8 to 11, 29 to 32, 36 to 39
- Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 1 to 14, 29 to 42
- Dose may be modified based on TPMT status
- Pegaspargase (Oncaspar) 2500 units/m2 IV over 1 to 2 hours once per day on days 15 & 43
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 15, 22, 43, 50
Supportive therapy
- Mesna (Mesnex) "is not required for this dose of cyclophosphamide, but may be administered at institutional discretion."
CNS therapy, prophylaxis
- Methotrexate (MTX) by the following age-based criteria, for CNS3:
- 1 to 1.99 years old: 8 mg IT once per day on days 1 & 8
- 2 to 2.99 years old: 10 mg IT once per day on days 1 & 8
- 3 to 8.99 years old: 12 mg IT once per day on days 1 & 8
- 9 years old or older: 15 mg IT once per day on days 1 & 8
50-day course
Subsequent treatment
- See protocol for details of treatment beyond consolidation, which is guided by MRD status obtained at the end of induction.
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
- COG AALL1231: Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. Epub 2022 Mar 10. link to original article link to PMC article PubMed NCT02112916
Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone
Regimen variant #1, high-dose MTX
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Asselin et al. 2011 (POG 9404) | 1996-2001 | Phase 3 (E-esc) | Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone; low-dose MTX | Seems to have superior EFS (primary endpoint) |
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
Chemotherapy
- Doxorubicin (Adriamycin) 30 mg/m2 (maximum dose of 60 mg) IV once per day on days 1, 2, 22
- Mercaptopurine (6-MP) 50 mg/m2 (maximum dose of 100 mg) PO once per day on days 22 to 36
- Methotrexate (MTX) 40 mg/m2 (maximum dose of 80 mg) (route not specified) once on day 2, given 8 to 24 hours after doxorubicin, then 500 mg/m2 (maximum dose of 1000 mg) IV over 30 minutes once on day 22, then 4500 mg/m2 (maximum dose of 9000 mg) IV continuous infusion over 23.5 hours
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV push once per week on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2/day (maximum dose of 80 mg/day) (route not specified) on days 1 to 22
Supportive therapy
- Dexrazoxane (Zinecard) 300 mg/m2 (maximum dose of 600 mg) IV once per day on days 1, 2, 22, given immediately before each dose of doxorubicin
42-day course
Regimen variant #2, low-dose MTX
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Asselin et al. 2011 (POG 9404) | 1996-2001 | Phase 3 (C) | Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone; high-dose MTX | Seems to have inferior EFS |
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
Chemotherapy
- Doxorubicin (Adriamycin) 30 mg/m2 (maximum dose of 60 mg) IV once per day on days 1, 2, 22
- Mercaptopurine (6-MP) 50 mg/m2 (maximum dose of 100 mg) PO once per day on days 22 to 36
- Methotrexate (MTX) 40 mg/m2 (maximum dose of 80 mg) (route not specified) once on day 2, given 8 to 24 hours after doxorubicin
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV push once per week on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2/day (maximum dose of 80 mg/day) (route not specified) on days 1 to 22
Supportive therapy
- Dexrazoxane (Zinecard) 300 mg/m2 (maximum dose of 600 mg) IV once per day on days 1, 2, 22, given immediately before each dose of doxorubicin
42-day course
References
- POG 9404: Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011 Jul 28;118(4):874-83. Epub 2011 Apr 7. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
Etoposide & TBI, then allo HSCT
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Peters et al. 2015 (ALL-SCT-BFM 2003) | 2003-2011 | Non-randomized |
Chemotherapy
- Etoposide (Vepesid) 60 mg/kg (maximum dose of 3600 mg) IV once on day -3
Radiotherapy
- Total body irradiation (TBI) 200 cGy twice per day in 6 fractions on days -6 to -4 with lung shielding at 1000 cGy (total dose: 1200 cGy)
Immunotherapy
- Allogeneic stem cells transfused on day 0
One course
References
- ALL-BFM 90: Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H; German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000 Jun 1;95(11):3310-22. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Subgroup analysis: Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006 Dec 20;24(36):5742-9. link to original article PubMed
- ALL-BFM 95: Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M; German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008 May 1;111(9):4477-89. Epub 2008 Feb 19. Erratum in: Blood. 2009 Apr 30;113(18):4478. Dosage error in article text. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Subgroup analysis: Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006 Dec 20;24(36):5742-9. link to original article PubMed
- ALL-SCT-BFM-2003: Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1265-74. Epub 2015 Mar 9. link to original article PubMed NCT01423747
L-asparaginase monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Amylon et al. 1999 (POG 8704) | 1987-1992 | Phase 3 (E-esc) | No L-asp | Superior CRR |
References
- POG 8704: Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar;13(3):335-42. link to original article dosing details in abstract have been reviewed by our editors PubMed
Interim maintenance
Mercaptopurine, Methotrexate, Vincristine
BFM HDMTX: Berlin Frankfurt Muenster High-Dose MTX (Methotrexate) regimen
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Winter et al. 2015 (COG AALL0434) | 2007-2014 | Phase 3 (C) | COG C-MTX | Seems to have inferior OS1 |
1Reported efficacy is based on the 2018 update.
Preceding treatment
Chemotherapy
- Mercaptopurine (6-MP) 25 mg/m2 PO once per day on days 1 to 56
- Methotrexate (MTX)
- Vincristine (Oncovin)
8-week course
Subsequent treatment
- Delayed intensification
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
Methotrexate, Pegaspargase, Vincristine
COG C-MTX: Children's Oncology Group Capizzi-style MTX (Methotrexate) regimen
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Winter et al. 2015 (COG AALL0434) | 2007-2014 | Phase 3 (C) | BFM HDMTX | Seems to have superior OS |
Details to be completed; reported efficacy is based on the 2018 update.
Preceding treatment
Subsequent treatment
- Delayed intensification
References
- COG AALL0434: Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00408005
- Update: Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018 Oct 10;36(29):2926-2934. Epub 2018 Aug 23. link to original article link to PMC article PubMed
- Update: Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. Epub 2020 Aug 19. link to original article link to PMC article PubMed
Relapsed or refractory
Mitoxantrone, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Parker et al. 2010 (CCLG ALL R3) | 2003-2007 | Phase 3, fewer than 20 pts in this subgroup (E-switch-ic) | Idarubicin, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone | Did not meet primary endpoint of PFS |
Note: per the protocol, this regimen is intended only for patients 18 and younger and for patients allergic to pegaspargase. This is the same regimen used in relapsed B-ALL, but this subgroup did not have a statistically significant difference between the regimens.
Chemotherapy
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 & 8
- Asparaginase Erwinia chrysanthemi (Erwinaze) 20,000 units IM once per day on days 3, 5, 7, 9, 11, 13, 18, 20, 22, 24, 26, 28
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 3, 10, 17, 24
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg/m2 PO once per day on days 1 to 5, 15 to 19
CNS therapy, prophylaxis
- Methotrexate (MTX) by the following age-based criteria:
- Younger than 2 years old: 8 mg IT once per day on days 1 & 8
- Age 2: 10 mg IT once per day on days 1 & 8
- Older than 2 years old: 12 mg IT once per day on days 1 & 8
4-week course
Subsequent treatment
- See paper for details of treatment beyond induction
References
- CCLG ALL R3: Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. Epub 2010 Dec 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00967057
Mitoxantrone, Pegaspargase, Vincristine, Dexamethasone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Parker et al. 2010 (CCLG ALL R3) | 2003-2007 | Phase 3, fewer than 20 pts in this subgroup (E-switch-ic) | Idarubicin, Pegaspargase, Vincristine, Dexamethasone | Did not meet primary endpoint of PFS |
Note: per the protocol, this regimen is intended only for patients 18 and younger. This is the same regimen used in relapsed B-ALL, but this subgroup did not have a statistically significant difference between the regimens.
Chemotherapy
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 & 8
- Pegaspargase (Oncaspar) 1000 units/m2 IM once per day on days 3 & 18
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 3, 10, 17, 24
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg/m2 PO once per day on days 1 to 5, 15 to 19
CNS therapy, prophylaxis
- Methotrexate (MTX) by the following age-based criteria:
- Younger than 2 years old: 8 mg IT once per day on days 1 & 8
- Age 2: 10 mg IT once per day on days 1 & 8
- Older than 2 years old: 12 mg IT once per day on days 1 & 8
4-week course
Subsequent treatment
- See paper for details of treatment beyond induction
References
- CCLG ALL R3: Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. Epub 2010 Dec 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00967057
Nelarabine monotherapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Berg et al. 2005 | 1997-2002 | Phase 2 (RT) | ORR: 14-55% |
Zwaan et al. 2017 (GSK 111081) | 2009-2014 | Phase 4 | ORR: 39% |
Chemotherapy
- Nelarabine (Arranon) 650 mg/m2 IV over 60 minutes once per day on days 1 to 5
21-day cycles
References
- Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20;23(15):3376-82. link to original article dosing details in abstract have been reviewed by our editors PubMed
- GSK 111081: Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, Ranganathan S, Leverger G. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017 Oct;179(2):284-293. Epub 2017 Aug 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00866671